[{"path":"https://higgi13425.github.io/medicaldata/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"MIT License","title":"MIT License","text":"Copyright (c) 2021 medicaldata authors Permission hereby granted, free charge, person obtaining copy software associated documentation files (“Software”), deal Software without restriction, including without limitation rights use, copy, modify, merge, publish, distribute, sublicense, /sell copies Software, permit persons Software furnished , subject following conditions: copyright notice permission notice shall included copies substantial portions Software. SOFTWARE PROVIDED “”, WITHOUT WARRANTY KIND, EXPRESS IMPLIED, INCLUDING LIMITED WARRANTIES MERCHANTABILITY, FITNESS PARTICULAR PURPOSE NONINFRINGEMENT. EVENT SHALL AUTHORS COPYRIGHT HOLDERS LIABLE CLAIM, DAMAGES LIABILITY, WHETHER ACTION CONTRACT, TORT OTHERWISE, ARISING , CONNECTION SOFTWARE USE DEALINGS SOFTWARE.","code":""},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"getting-started","dir":"Articles","previous_headings":"","what":"Getting Started","title":"making_tables","text":"First, set working environment loading 4 packages using library() function. Note can copy code blocks hovering top right corner, clicking copy icon appears, paste local version R run .","code":"library(medicaldata) suppressMessages(library(tidyverse)) suppressMessages(library(janitor)) suppressMessages(library(flextable))"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"counting-data-in-tables","dir":"Articles","previous_headings":"","what":"Counting Data in Tables","title":"making_tables","text":"common count data, particularly categories, summarize characteristics outcomes. tabyl function {janitor} package helpful . vignette, look use function make simple tables counts data. First, read data strep_tb indo_rct use tables. Load libraries setup chunk . run code chunk , two new data objects Environment tab.","code":"strep_tb <- medicaldata::strep_tb indo_rct <- medicaldata::indo_rct"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"table-2-from-streptomycin-for-tuberculosis","dir":"Articles","previous_headings":"","what":"Table 2 from Streptomycin for Tuberculosis","title":"making_tables","text":"now try reproduce Table 2 Streptomycin Tuberculosis manuscript, can found page 771. primary endpoint results, summarized 6 rows x 2 columns table (added totals row). Let’s walk tabyl() function {janitor} package.","code":""},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"first-table","dir":"Articles","previous_headings":"","what":"First Table","title":"making_tables","text":"tabyl() function allows pipe data tables, add ‘adornments’ like total rows percentages. Let’s start basic one-variable tabyl using ordinal endpoint. can pipe dataset tabyl function, desired variable (radiologic_6m) argument function. gives us n proportion level primary outcome.","code":"strep_tb %>%    tabyl(radiologic_6m) #>                 radiologic_6m  n    percent #>    6_Considerable_improvement 32 0.29906542 #>        5_Moderate_improvement 23 0.21495327 #>                   4_No_change  5 0.04672897 #>      3_Moderate_deterioration 17 0.15887850 #>  2_Considerable_deterioration 12 0.11214953 #>                       1_Death 18 0.16822430"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"two-variable-table","dir":"Articles","previous_headings":"","what":"Two Variable Table","title":"making_tables","text":"add treatment arm variable 2nd argument, can come closer original table. Note levels first argument make rows table, levels 2nd argument make columns (standard R x C order). Also note 2 variables, get counts default, proportions level, might want proportions column-wise, row-wise.","code":"strep_tb %>%    tabyl(radiologic_6m, arm) #>                 radiologic_6m Streptomycin Control #>    6_Considerable_improvement           28       4 #>        5_Moderate_improvement           10      13 #>                   4_No_change            2       3 #>      3_Moderate_deterioration            5      12 #>  2_Considerable_deterioration            6       6 #>                       1_Death            4      14"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"add-a-total-row","dir":"Articles","previous_headings":"","what":"Add A Total Row","title":"making_tables","text":"closer, lacks total row, percentages. order numbers calculate totals, start total row first. ‘adorn’ table totals row. specify want additional row totals bottom (column row-wise totals new column right), argument adorn_totals function.","code":"strep_tb %>%    tabyl(radiologic_6m, arm) %>%    adorn_totals(where = \"row\") # add a total row #>                 radiologic_6m Streptomycin Control #>    6_Considerable_improvement           28       4 #>        5_Moderate_improvement           10      13 #>                   4_No_change            2       3 #>      3_Moderate_deterioration            5      12 #>  2_Considerable_deterioration            6       6 #>                       1_Death            4      14 #>                         Total           55      52"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"add-percentages-and-formatting","dir":"Articles","previous_headings":"","what":"Add Percentages and formatting","title":"making_tables","text":"closer. Now need add percentages, percentage formatting. need specify want column-wise, rather row-wise percentages. adorn_ns add counts, counts percentages. can specify want counts listed first, argument position = \"front\" adorn_ns function.","code":"strep_tb %>%    tabyl(radiologic_6m, arm) %>% #2 dimensional table, RxC   adorn_totals(where = \"row\") %>% # add totals row   adorn_percentages(\"col\") %>%  # column-wise percentages   adorn_pct_formatting() %>%    adorn_ns(position = \"front\")  # put n first #>                 radiologic_6m Streptomycin     Control #>    6_Considerable_improvement  28  (50.9%)  4   (7.7%) #>        5_Moderate_improvement  10  (18.2%) 13  (25.0%) #>                   4_No_change   2   (3.6%)  3   (5.8%) #>      3_Moderate_deterioration   5   (9.1%) 12  (23.1%) #>  2_Considerable_deterioration   6  (10.9%)  6  (11.5%) #>                       1_Death   4   (7.3%) 14  (26.9%) #>                         Total  55 (100.0%) 52 (100.0%)"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"making-it-pretty","dir":"Articles","previous_headings":"","what":"Making it Pretty","title":"making_tables","text":"can pipe table flextable() object, makes easy add fancy formatting. many formatting options flextable package, can learn . can control column width, fonts, colors, much flextable format. Flextables can output MS Word, powerpoint, HTML, PDF, Rmarkdown. radiologic_6m Streptomycin Control 6_Considerable_improvement 28  (50.9%) 4   (7.7%) 5_Moderate_improvement 10  (18.2%) 13  (25.0%) 4_No_change 2   (3.6%) 3   (5.8%) 3_Moderate_deterioration 5   (9.1%) 12  (23.1%) 2_Considerable_deterioration 6  (10.9%) 6  (11.5%) 1_Death 4   (7.3%) 14  (26.9%) Total 55 (100.0%) 52 (100.0%)","code":"strep_tb %>%    tabyl(radiologic_6m, arm) %>%    adorn_totals(where = \"row\") %>%    adorn_percentages(\"col\") %>%  # column-wise percentages   adorn_pct_formatting() %>%    adorn_ns(position = \"front\") %>%   # put n first   flextable::flextable()"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"try-this-yourself","dir":"Articles","previous_headings":"","what":"Try this Yourself","title":"making_tables","text":"Now try , instead using ordinal radiologic_6m outcome, use improved dichotomous outcome place. Copy code block add piping additional lines produce 2 x 2 table outcomes. can websearch janitor tabyl adorn_title learn add title table.","code":"strep_tb #> # A tibble: 107 × 13 #>    patient_id arm     dose_strep_g dose_PAS_g gender baseline_condition #>    <chr>      <fct>          <dbl>      <dbl> <fct>  <fct>              #>  1 0001       Control            0          0 M      1_Good             #>  2 0002       Control            0          0 F      1_Good             #>  3 0003       Control            0          0 F      1_Good             #>  4 0004       Control            0          0 M      1_Good             #>  5 0005       Control            0          0 F      1_Good             #>  6 0006       Control            0          0 M      1_Good             #>  7 0007       Control            0          0 F      1_Good             #>  8 0008       Control            0          0 M      1_Good             #>  9 0009       Control            0          0 F      2_Fair             #> 10 0010       Control            0          0 M      2_Fair             #> # ℹ 97 more rows #> # ℹ 7 more variables: baseline_temp <fct>, baseline_esr <fct>, #> #   baseline_cavitation <fct>, strep_resistance <fct>, radiologic_6m <fct>, #> #   rad_num <dbl>, improved <lgl>"},{"path":"https://higgi13425.github.io/medicaldata/articles/making_tables.html","id":"challenge","dir":"Articles","previous_headings":"","what":"Challenge","title":"making_tables","text":"Now try indo_rct dataset, using treatment variable group outcome variable outcome. Add total row, percentages, title.","code":"indo_rct  #> # A tibble: 602 × 33 #>       id site    age  risk gender   outcome sod   pep   recpanc psphinc precut #>    <dbl> <fct> <dbl> <dbl> <fct>    <fct>   <fct> <fct> <fct>   <fct>   <fct>  #>  1  1001 1_UM     26   2   1_female 1_yes   1_yes 0_no  1_yes   0_no    0_no   #>  2  1002 1_UM     24   1   2_male   0_no    0_no  1_yes 0_no    0_no    0_no   #>  3  1003 1_UM     57   1   1_female 0_no    1_yes 0_no  0_no    0_no    0_no   #>  4  1004 1_UM     29   2   1_female 1_yes   1_yes 0_no  0_no    0_no    0_no   #>  5  1005 1_UM     38   3.5 1_female 0_no    1_yes 1_yes 0_no    1_yes   0_no   #>  6  1006 1_UM     59   3   1_female 0_no    1_yes 0_no  0_no    0_no    1_yes  #>  7  1007 1_UM     60   1.5 1_female 0_no    0_no  0_no  1_yes   0_no    0_no   #>  8  1008 1_UM     29   1   2_male   0_no    0_no  0_no  0_no    0_no    0_no   #>  9  1009 1_UM     53   2   2_male   0_no    0_no  0_no  1_yes   0_no    0_no   #> 10  1010 1_UM     20   2   2_male   0_no    0_no  0_no  0_no    0_no    1_yes  #> # ℹ 592 more rows #> # ℹ 22 more variables: difcan <fct>, pneudil <fct>, amp <fct>, paninj <fct>, #> #   acinar <fct>, brush <fct>, asa81 <fct>, asa325 <fct>, asa <fct>, #> #   prophystent <fct>, therastent <fct>, pdstent <fct>, sodsom <fct>, #> #   bsphinc <fct>, bstent <fct>, chole <fct>, pbmal <fct>, train <fct>, #> #   status <fct>, type <fct>, rx <fct>, bleed <dbl>"},{"path":"https://higgi13425.github.io/medicaldata/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Peter Higgins. Author, maintainer.","code":""},{"path":"https://higgi13425.github.io/medicaldata/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Higgins P (2023). medicaldata: Data Package Medical Datasets. https://higgi13425.github.io/medicaldata/, https://github.com/higgi13425/medicaldata/.","code":"@Manual{,   title = {medicaldata: Data Package for Medical Datasets},   author = {Peter Higgins},   year = {2023},   note = {https://higgi13425.github.io/medicaldata/, https://github.com/higgi13425/medicaldata/}, }"},{"path":[]},{"path":"https://higgi13425.github.io/medicaldata/index.html","id":"overview","dir":"","previous_headings":"","what":"Overview","title":"An R Package Of Medical Data For Teaching","text":"data package 19 medical datasets teaching Reproducible Medical Research R. link pkgdown reference website {medicaldata} links right. package useful anyone teaching R medical professionals, including doctors, nurses, pharmacists, trainees, students.  datasets range reconstructed versions James Lind’s scurvy dataset (1757) original Streptomycin Tuberculosis trial (1948), 2012 RCT indomethacin prevent post-ERCP pancreatitis involved , cohort data SARS-CoV2 testing results (2020). Many datasets come American Statistical Association’s TSHS (Teaching Statistics Health Sciences) Resources Portal, maintained Carol Bigelow University Massachusetts (permission). growing number datasets dev version generously donated Frank Harrell website . datasets currently dev version package github.com, make CRAN June 2023.","code":""},{"path":"https://higgi13425.github.io/medicaldata/index.html","id":"how-to-install-and-use-medicaldata-datasets","dir":"","previous_headings":"","what":"How to Install and Use {medicaldata} Datasets","title":"An R Package Of Medical Data For Teaching","text":"Install stable, current CRAN version install.packages(\"medicaldata\"). want try -development version (may new datasets vignettes, may also intermittently wonky), install : remotes::install_github(\"higgi13425/medicaldata\") load package library(medicaldata) can list datasets available data(package = \"medicaldata\") assign particular dataset named object environment : covid <- medicaldata::covid_testing  covid name new object, covid_testing name dataset. Articles (vignettes) use datasets can found pkgdown website Articles tab. can click links view description document /codebook dataset. information also available Reference tab , within R using help(dataset_name).","code":""},{"path":"https://higgi13425.github.io/medicaldata/index.html","id":"please-donate-datasets","dir":"","previous_headings":"","what":"Please Donate Datasets","title":"An R Package Of Medical Data For Teaching","text":"access data randomized, controlled clinical trial, prospective cohort study, even case-control study, please consider obtaining appropriate permissions, anonymizing data, donating dataset teaching purposes add package. Open issue github page (source code link top right) open discussion data donation. happy help anonymization.","code":""},{"path":"https://higgi13425.github.io/medicaldata/index.html","id":"list-of-datasets","dir":"","previous_headings":"","what":"List of Datasets","title":"An R Package Of Medical Data For Teaching","text":"Click links details dataset Description Document, details variables included dataset Codebook. Note dataset also help file can use within R RStudio, entering help(\"dataset_name\") Console pane. fourth column table (scroll right widen browser window) describes study design, requested Dan Sjoberg {gtsummary} fame.","code":""},{"path":"https://higgi13425.github.io/medicaldata/index.html","id":"messy-datasets","dir":"","previous_headings":"","what":"Messy Datasets","title":"An R Package Of Medical Data For Teaching","text":"beta test messy datasets, largely Excel, many annoying non-tidy non-rectangular features help teach data cleaning/wrangling. actually package (R files), can found GitHub repository. can download open GitHub repo messy Excel glory clicking URL links table . can also find list GitHub repo, can click one *.xlsx files, click View Raw button download . can read datasets directly R urls table example code found following code chunk, reads messy_infarct dataset assigns object infarct. may easiest copy entire code chunk hovering copy icon top right corner, clicking copy.","code":"# install.packages('openxlsx') # if not already installed library(openxlsx) url <- \"https://github.com/higgi13425/medicaldata/raw/master/data-raw/messy_data/messy_infarct.xlsx\" # replace the filename \"messy_infarct.xlsx\" at the end of this long url path with the filename that you want to load.  # Or just copy the whole path from the URL column below. infarct <- openxlsx::read.xlsx(url) head(infarct)"},{"path":[]},{"path":"https://higgi13425.github.io/medicaldata/reference/abm.html","id":null,"dir":"Reference","previous_headings":"","what":"Observational Dataset of Acute Bacterial Meningitis — abm","title":"Observational Dataset of Acute Bacterial Meningitis — abm","text":"dataset subset data Duke University study acute meningitis, provided Frank Harrell website . patients found clinical symptoms meningitis, include painful, stiff neck limited range motion, headache, light sensitivity, high fever, confusion, lethargy. can progress rapidly, prove fatal. Bacterial meningitis can treated successfully antibiotics, given early. Antibiotics unnecessary unhelpful viral meningitis, can cause allergic reactions adverse events patients. Clinically, viral bacterial meningitis similar symptoms, due common cause inflammation meninges, three membranous layers protect brain spinal cord. spinal tap (lumbar puncture) can performed obtain cerebrospinal fluid (CSF) analysis help classify cases bacterial viral origin.  Timely classification early treatment bacterial meningitis can life-saving.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/abm.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Observational Dataset of Acute Bacterial Meningitis — abm","text":"","code":"abm"},{"path":"https://higgi13425.github.io/medicaldata/reference/abm.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Observational Dataset of Acute Bacterial Meningitis — abm","text":"data frame 581 observations 22 variables casenum case number, 1 581; type: double year 2 digit year, 68 (1968) 80 (1980), 72 missing; type: double month month, 1 (January) 12 (December), 81 missing; type: double age age years, 81 missing; type: double race coded 1 = Black, 2 = White, 85 missing; type: double sex gender, coded 0 = male 1 = female, 81 missing; type: double blood_wbc white blood cell count blood, thousands cells per cubic millimeter, 141 missing; type: double blood_neut_pct Percentage white blood cells neutrophils, considered indicative acute bacterial infection, blood, 146 missing; type: double blood_band_pct Band cells, also known immature neutrophils, considered indicative acute bacterial infection, blood, percent total white blood cells, 153 missing; type: double blood_gluc Blood glucose, milligrams per deciliter, 258 missing; type: double csf_gluc CSF (cerebrospinal fluid) glucose, milligrams per deciliter, 129 missing; type: double csf_prot CSF (cerebrospinal fluid) protein, milligrams per deciliter, 249 missing; type: double csf_rbc CSF (cerebrospinal fluid) red blood cells, thousands cells per cubic millimeter, 271 missing; type: double csf_wbc CSF (cerebrospinal fluid) white blood cells, thousands cells per cubic millimeter, 101 missing; type: double csf_neut_pct CSF (cerebrospinal fluid) neutrophil percentage, percent total white blood cells CSF, 132 missing; type: double csf_mono_pct CSF (cerebrospinal fluid) monocyte percentage, percent total white blood cells CSF, 165 missing; type: double csf_lymph_pct CSF (cerebrospinal fluid) lymphocyte percentage, percent total white blood cells CSF, 162 missing; type: double gram gram stain result, values 0-6, 313 missing; type: double csf_cult result csf culture bacterial growth, values 0-6, 307 missing; type: double blood_cult result blood culture bacterial growth, values 0-6, 434 missing, 11; type: double subset subset, training = 1 test = 2; type: double abm outcome variable, acute bacterial meningitis, 0 = absent 1 = present, 80 missing; type: double","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/abm.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Observational Dataset of Acute Bacterial Meningitis — abm","text":"data set provided generously Frank Harrell, website , dataset \"abm\". data published Spanos , Harrell FE, Durack DT (1989): Differential diagnosis acute meningitis: analysis predictive value initial observations. JAMA 262: 2700-2707, can found .","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/abm.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Observational Dataset of Acute Bacterial Meningitis — abm","text":"Bacterial meningitis occurs 1 100,000 people per year United States, commonly people 16 23 years old, additional age peaks infants young children, elderly. Early symptoms include headache, fever, pinprick rash reddish-purple tiny spots. peak season bacterial meningitis dry winter months hemisphere (December-February Northern Hemisphere). Bacterial meningitis fatality rate 15-20%, higher elderly. Untreated bacterial meningitis due Streptococcus pneumoniae H. influenzae approaches 100% mortality.  Viral meningitis generally resolves supportive care, bacterial meningitis requires early use antibiotic therapy. subset patients require head CT (computed tomography) scan lumbar puncture obtain CSF, must occur antibiotics given. CSF (cerebrospinal fluid) sent lab cell count differential, glucose, protein, gram stain, culture. Normally, meninges part blood-brain barrier, keeps assorted toxins ingest brain. Proteins large molecules bloodstream able reach CSF normally, even smaller molecules like glucose equilibrate slowly, CSF glucose lags behind changes blood glucose. Normal CSF white blood cells, around 70% lymphocytes 30% monocytes, neutrophils. bacteria begin multiply CSF, CSF protein levels go , glucose consumed, white blood cells (largely neutrophils) arrive fight bacteria. Viral infections tend attract lymphocytes monocytes. Characteristic findings bacterial meningitis include low CSF glucose, low CSF serum glucose ratio, high CSF protein, high CSF white blood cell count, usually composed neutrophils. However, spectrum CSF values bacterial meningitis wide one findings little value. 20% lumbar punctures draw bit blood, seen 100,000 RBCs per cubic mm. blood also increase CSF WBCs one WBC per every 500-1000 RBCs, may require adjustment WBC number.  Empiric treatment antibiotics begun soon CSF reaches lab, often combination ceftriaxone plus vancomycin, ampicillin added elderly cover Listeria. Meropenem often used immunocompromised broader coverage including Listeria Pseudomonas. gram stain helps detect bacteria CSF, ~60% sensitive, usually miss tuberculosis, toxoplasmosis, fungal meningitis. CSF culture (growing bacteria) sensitive, takes several days. primary analysis task classify viral (abm = 0) vs. bacterial (abm = 1) cases, published Spanos , Harrell FE, Durack DT (1989): Differential diagnosis acute meningitis: analysis predictive value initial observations. JAMA 262: 2700-2707. data 581 patients, typical levels missing data clincial observational studies done days paper charts, may choose impute missing data. variables published paper need derived, including CSF blood glucose ratio, number months peak summer (North Carolina, Northern Hemisphere). addition imputation, modern machine learning classification techniques can applied compared logistic regression.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/blood_storage.html","id":null,"dir":"Reference","previous_headings":"","what":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","title":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","text":"data set contains data 316 men undergone radical prostatectomy received transfusion within 30 days surgical procedure available prostate serum antigen (PSA) follow-data. main exposure interest RBC storage duration group. number demographic, baseline prognostic factors also collected. outcome time biochemical (PSA) cancer recurrence. dataset cleaned complete. outliers data problems (details variable information).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/blood_storage.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","text":"","code":"blood_storage"},{"path":"https://higgi13425.github.io/medicaldata/reference/blood_storage.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","text":"data frame 316 observations 20 variables RBC.Age.Group NA, numeric, range: 1.00-  3 Median.RBC.Age NA, numeric, range:10.00- 25 Age NA, numeric, range:38.40- 79 AA NA, numeric, range: 0.00-  1 FamHx NA, numeric, range: 0.00-  1 PVol NA, numeric, range:19.40-274 TVol NA, numeric, range: 1.00-  3 T.Stage NA, numeric, range: 1.00-  2 bGS NA, numeric, range: 1.00-  3 BN+ NA, numeric, range: 0.00-  1 OrganConfined NA, numeric, range: 0.00-  1 PreopPSA NA, numeric, range: 1.30- 40 PreopTherapy NA, numeric, range: 0.00-  1 Units NA, numeric, range: 1.00- 19 sGS NA, numeric, range: 1.00-  4 AnyAdjTherapy NA, numeric, range: 0.00-  1 AdjRadTherapy NA, numeric, range: 0.00-  1 Recurrence NA, numeric, range: 0.00-  1 Censor NA, numeric, range: 0.00-  1 TimeToRecurrence NA, numeric, range: 0.27-104","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/blood_storage.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","text":"Cata et al. 'Blood Storage Duration Biochemical Recurrence Cancer Radical Prostatectomy'. Mayo Clin Proc 2011; 86(2): 120-127.","code":""},{"path":[]},{"path":"https://higgi13425.github.io/medicaldata/reference/blood_storage.html","id":"background","dir":"Reference","previous_headings":"","what":"Background","title":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","text":"Prostate cancer common malignant neoplasm men, radical prostatectomy among primary therapies localized prostate cancer. biochemical recurrence-free survival rate 5 years prostatectomy ranges 70% 90%. Improvements surgical technique decreased amount intraoperative blood loss occurring radical prostatectomy; however, substantial numbers patients still require perioperative blood transfusions. Blood transfusions associated adverse reactions, including postoperative infections transfusion-related immune perturbations. Allogeneic leukocytes present transfused blood thought suppress host cellular immune responses. Furthermore, immunodepressant effect secondary imbalance accumulated cytokines proinflammatory mediators transfused blood decreased production lymphocyte stimulating cell-mediated cytokines, interleukin 2 increased release immunosuppressive prostaglandins patient undergoing transfusion. cancer patients, perioperative blood transfusion long suspected reducing long-term survival, available evidence inconsistent. also unclear components transfused blood underlie cancer-promoting effects reported studies. important factor associated deleterious effects blood transfusion storage age transfused blood units. suspected cancer recurrence may worsened transfusion older blood.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/blood_storage.html","id":"study-objective","dir":"Reference","previous_headings":"","what":"Study Objective","title":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","text":"study evaluated association red blood cells (RBC) storage duration biochemical prostate cancer recurrence radical prostatectomy. Specifically, tested hypothesis perioperative transfusion allogeneic RBCs stored prolonged period associated earlier biochemical recurrence prostate cancer prostatectomy.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/blood_storage.html","id":"subjects-and-variables","dir":"Reference","previous_headings":"","what":"Subjects and Variables","title":"Retrospective Cohort Study of the Effects of Blood Storage on Prostate Cancer — blood_storage","text":"Patients assigned 1 3 RBC age exposure groups basis terciles (ie, 33rd 66th percentiles) overall distribution RBC storage duration transfused units loosely characterized 'younger,' 'middle,' 'older' age. Although approach resulted removal certain patients wide RBC age distributions, advantage defining essentially random clearly separable exposure. Prostate-specific antigen (PSA) used biochemical marker prostate cancer recurrence prostatectomy. PSA value least 0.4 ng/mL (convert microg/L, multiply 1.0) followed another increase considered biochemical cancer recurrence. initial population consisted 865 men undergone radical prostatectomy received transfusion within 30 days surgical procedure Cleveland Clinic available PSA follow-data. patients, 110 excluded analysis received combination allogeneic autologous blood products. remaining 755 patients, 405 (54%) received solely allogeneic 350 patients (46%) received solely autologous RBC units. 405 patients received allogeneic RBC transfusion, 89 excluded transfused RBC age distribution included one terciles. Thus, dataset consists 316 patients received solely allogeneic blood products classified RBC age exposure group.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cath.html","id":null,"dir":"Reference","previous_headings":"","what":"Observational Dataset of Cardiac Catheterization — cath","title":"Observational Dataset of Cardiac Catheterization — cath","text":"dataset Duke University Cardiovascular Disease Databank, provided Frank Harrell https://hbiostat.org. patients referred Duke University Medical Center chest pain. Cardiac catheterization (also known 'cath') performed diagnose open blockages arteries, often followed stenting keep open. (PDRH) intern Duke 2001, nightly occurrence 'cath bus' arrive Lumberton, North Carolina 8 patients chest pain (), lighting pager cardiology intern multiple requests nitroglycerin.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cath.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Observational Dataset of Cardiac Catheterization — cath","text":"","code":"cath"},{"path":"https://higgi13425.github.io/medicaldata/reference/cath.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Observational Dataset of Cardiac Catheterization — cath","text":"data frame 3504 observations 6 variables sex gender, coded 0=male 1=female; type: double age age years; type: double cad_dur duration symptoms chest pain, days; type: double choleste serum cholesterol level milligrams per deciliter. Note 35.56% observations cholesterol missing; type: double sigdz significant coronary artery disease found cardiac catheterization: 0=, 1=yes; type: double tvdlm three vessel left main coronary artery disease found cardiac catheterization. 3 missing observations tvdlm: 0=, 1=yes; type: double","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cath.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Observational Dataset of Cardiac Catheterization — cath","text":"data set provided generously Frank Harrell, website , dataset \"acath\".","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cath.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Observational Dataset of Cardiac Catheterization — cath","text":"Coronary artery disease, atherosclerosis blood vessels supplying heart, common cause death United States. Duke University Medical Center located southeastern US, region highly prevalent coronary artery disease (CAD), associated frequent smoking, diabetes, obesity, along genetic risk factors early-onset CAD local Lumbee Indian tribe.  catheterization, reduction artery diameter least 75% considered significant reduction blood flow puts downstream heart muscle risk ischemia. Significant coronary disease can treated multiple medications, opening partially blocked artery. done via catheter blood vessels wrist groin, threaded blood vessels heart. location blockage, narrowed area can opened balloon, newly opened artery kept open carefully placed coronary stent.  sigdz variable indicator presence blockage least 75% one left main coronary artery three distributing arteries - LAD, LCA, RCA. tvdlm variable indicator one two results catheterization. One three vessel disease - blockages three left anterior descendig (LAD) coronary artery, left circumflex coronary artery (LCA), right coronary artery (RCA). occurs commonly association diabetes, longstanding severe CAD. left main disease, blockage artery feeds LAD LCA. Blockage left main coronary artery frequently fatal, colloquially known \"widowmaker\".  interesting potential analyses include predicting probability significant (>= 75% diameter narrowing least one major coronary artery) coronary disease, predicting probability severe coronary disease given significant disease present. first analysis use sigdz response variable, second use tvdlm subset patients sigdz=1.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cdystonia.html","id":null,"dir":"Reference","previous_headings":"","what":"RCT of Botulinum Toxin B for Cervical Dystonia — cdystonia","title":"RCT of Botulinum Toxin B for Cervical Dystonia — cdystonia","text":"Longitudinal esults randomized, placebo-controlled trial botulinum toxin type B (BotB) 109 subjects across 9 sites. (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cdystonia.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"RCT of Botulinum Toxin B for Cervical Dystonia — cdystonia","text":"","code":"cdystonia"},{"path":"https://higgi13425.github.io/medicaldata/reference/cdystonia.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"RCT of Botulinum Toxin B for Cervical Dystonia — cdystonia","text":"data frame 631 observations 7 variables week week measurement; type: numeric site study site, levels: 1-9; type: double id patient id site (unique across sites); type: numeric 1-19 treat treatmentm assignment: levels: placebo, BotB5000, BotB10000; type: double 1-3) age age years, range 26-83; type: numeric sex sex participant, 1 = F, 2 = M; type: double twstrs total score Toronto Western Spasmodic Torticollis Rating Scale, range 0-87; type: numeric","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cdystonia.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"RCT of Botulinum Toxin B for Cervical Dystonia — cdystonia","text":"data set study published 1999 journal Neurology, . Brashear, M.F. Lew, D.D. Dykstra, C.L. Comella, S.. Factor, R.L. Rodnitzky, R. Trosch, C. Singer, M.F. Brin, J.J. Murray, J.D. Wallace, . Willmer–Hulme, M. Koller (1999), Safety efficacy NeuroBloc (botulinum toxin type B) type –responsive cervical dystonia. Neurology, 53(7), 1439. dataset passed Statistical Methods Analysis Repeated Measurements Charles S. Davis, pp. 161-163 (Springer, 2002) can also found Frank Harrell's website .","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cdystonia.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"RCT of Botulinum Toxin B for Cervical Dystonia — cdystonia","text":"Cervical dystonia, also called spasmodic torticollis, painful condition neck muscles contract involuntarily, causing head twist turn one side. Cervical dystonia can also cause head uncontrollably tilt forward backward.  rare disorder can occur age, cervical dystonia often occurs middle-aged people, women men. Symptoms generally begin gradually reach point get substantially worse. 109 subjects across 9 sites randomized placebo (N = 36), 5000 units botulinum toxin B (N = 36), 10,000 units botulinum toxin B (N = 37), injected affected muscle partially paralyze make relax, releasing spasmed side neck head. response variable score Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS-Total 0-87 scale), measures severity, pain, disability cervical dystonia (higher scores mean impairment) weeks 0 (baseline), 2, 4, 8, 12, 16. expected single botox injection week 0 may wear time.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/covid_testing.html","id":null,"dir":"Reference","previous_headings":"","what":"Deidentified Results of COVID-19 testing at the Children's Hospital of Pennsylvania (CHOP) in 2020 — covid_testing","title":"Deidentified Results of COVID-19 testing at the Children's Hospital of Pennsylvania (CHOP) in 2020 — covid_testing","text":"dataset containing details SARS-CoV-2 testing 2020 CHOP","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/covid_testing.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Deidentified Results of COVID-19 testing at the Children's Hospital of Pennsylvania (CHOP) in 2020 — covid_testing","text":"","code":"covid_testing"},{"path":"https://higgi13425.github.io/medicaldata/reference/covid_testing.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Deidentified Results of COVID-19 testing at the Children's Hospital of Pennsylvania (CHOP) in 2020 — covid_testing","text":"data frame 15524 observations 17 variables subject_id id number subject; type: numeric fake_first_name auto-generated fake first name; type: character fake_last_name auto-generated fake last name; character gender anonymized Gender, levels: female, male; type: character pan_day day start pandemic; type: numeric test_id test performed, levels: covid, xcvd1; type: character clinic_name Clinic ward specimen collected, 88 levels; type: character result result test, levels: positive, negative, invalid; type: character demo_group patient group, levels: patient, misc_adult, client, adult, unidentified; type: character age Age subject time specimen collection (Anonymized), units = years; type: numeric drive_thru_ind Whether specimen collected via drive-thru site, levels: 1: Collected drive-thru site; 0: collected drive-thru site; type: numeric ct_result Cycle threshold reached PCR, range: 14.05-45; type: numeric orderset Whether order set used test order, levels: 1: Collected via orderset; 0: collected via orderset; numeric payor_group Payor associated order, levels: commercial, government, unassigned, medical assistance, self pay, charity care, ; type: character patient_class Disposition subject time collection, levels: inpatient, emergency, observation, recurring outpatient, outpatient, applicable, day surgery, admit surgery-obs, admit surgery-ip; type: character col_rec_tat Time elapsed collect time receive time, range: 0 - 61370.2, units = hours; type: numeric rec_ver_tat Time elapsed receive time verification time, range: -18.6 - 218.2, units = hours; type: numeric","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/covid_testing.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Deidentified Results of COVID-19 testing at the Children's Hospital of Pennsylvania (CHOP) in 2020 — covid_testing","text":"data set Amrom E. Obstfeld, de-identified data COVID-19 testing 2020 CHOP (Children's Hospital Pennsylvania). data set contains data concerning testing SARS-CoV2 via PCR well associated metadata. data anonymized, time-shifted, permuted.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/covid_testing.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Deidentified Results of COVID-19 testing at the Children's Hospital of Pennsylvania (CHOP) in 2020 — covid_testing","text":"Data testing SARS-CoV2 days 4-107 COVID pandemic 2020. CHOP pediatric hospital Philadelphia, Pennsylvania, USA. data anonymized, time-shifted, permuted.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":null,"dir":"Reference","previous_headings":"","what":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"data set contains 64 consecutive patients underwent T-cell replete, matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. primary risk factor interest number activating killer immunoglobulin-like receptors (aKIRs: 1-4 vs. 5-6). (details variable information).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"","code":"cytomegalovirus"},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"data frame 64 observations 26 variables ID Patient ID, numeric, range:  1-64 age Recipient age transplant, numeric, range: 29-67 sex Recipient sex, numeric, range:  0 (male) - 1(female) race Recipient race, numeric, range:  0 (white) - 1 (african-american) diagnosis type: character, levels: 13 diagnosis.type Category cancer diagnosis, numeric, range:  0 (myeloid) - 1 (lymphoid) time..transplant Time cancer diagnosis transplant (months), numeric, range:  1.84-173.8 prior.radiation Prior radiation therapy, numeric, range:  0 () - 1 (yes) prior.chemo Number prior chemotherapy regimens, numeric, range:  0-8 prior.transplant Prior stem cell transplant, numeric, range:  0 () - 1 (yes) recipient.cmv Recipient cytomegalovirus seropositive status, numeric, range:  0 (negative) - 1 (positive) donor.cmv Donor cytomegalovirus seropositive status, numeric, range:  0 (negative) - 1 (positive) donor.sex Donor sex, numeric, range:  0 (female) - 1 (male) TNC.dose Total nucleated cell dose (x 10^8/kg), numeric, range:  2.06- 21.0 CD34.dose Total CD34+ (stem) cell dose (x 10^8/kg), numeric, range:  2.04- 12.5 CD3.dose Total CD3+ (T) cell dose (x 10^8/kg), numeric, range:  1.08-  8.2 CD8.dose Total CD8+ cell dose (x 10^8/kg), numeric, range:  0.16-  3.2 TBI.dose Total body irradiation dosage (centiGrays), numeric, range:200.00-400.0 C1/C2 HLA-Cw group, numeric, range:  0 (heterozygous) - 1 (homozygous) aKIRs Number donor activating killer immunoglobulin-like receptors (hypothesized Predictor), numeric, range:  1.00-  6.0 cmv cytomegalovirus reactivation posttransplant (hypothesized Outcome), numeric, range:  0 () - 1 (Yes) time..cmv Time cytomegalovirus reactivation (months), numeric, range:  0.43- 84.5 agvhd Acute level 2-4 graft versus host disease, numeric, range:  0 () - 1 (yes) time..agvhd Time acute level 2-4 graft versus host disease (months), numeric, range:  0.66- 85.2 cgvhd Chronic graft versus host disease, numeric, range:  0 () - 1 (yes) time..cgvhd Time chronic graft versus host disease (months), numeric, range:  0.82- 65.1","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"Sobecks et al. 'Cytomegalovirus Reactivation Matched Sibling Donor Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant Correlates Donor Killer Immunoglobulin-like Receptor Genotype'. Exp Clin Transplant 2011; 1: 7-13.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"number demographic, baseline transplant characteristics also collected. primary outcome presence time cytomegalovirus reactivation. dataset cleaned relatively complete. outliers data problems.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":"background","dir":"Reference","previous_headings":"","what":"Background","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"Hematopoietic stem cell transplantation (HSCT) transplantation multipotent hematopoietic stem cells, bone marrow, peripheral blood, umbilical cord blood. medical procedure often performed patients certain cancers blood bone marrow, multiple myeloma leukemia. Allogeneic HSCT involves two people: (healthy) donor (patient) recipient. Allogeneic HSC donors must tissue (HLA) type matches recipient.  myeloablative allogeneic HSCT, chemotherapy irradiation given immediately prior transplant (conditioning regimen) purpose eradicating patient's disease prior infusion HSC suppress immune reactions. bone marrow can ablated (destroyed) dose- levels cause minimal injury tissues. many patients high risk transplant-related mortality myeloablative allogeneic HSCT, reduced- intensity conditioning allogeneic hematopoietic stem cell transplant proven effective. Although reduced-intensity conditioning allogeneic HSCT may avoid many organ toxicities associated myeloablative conditioning, risk developing graft-versus-host disease infection including cytomegalovirus remains significant. Cytomegalovirus (CMV) common virus can infect almost anyone. infected, body retains virus life. people know CMV rarely causes problems healthy people. pregnant weakened immune system, CMV cause concern. people compromised immunity, allogeneic HSCT, CMV infection can fatal. Natural killer (NK) T cells provide protection CMV reactivation. reactivity NK cells T-cell subsets regulated interaction killer immunoglobulin-like receptors (KIRs) target cell HLA class 1 molecules. donor activating KIR genotype implicated contributing factor CMV reactivation myeloablative allogeneic HSCT.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":"study-objective","dir":"Reference","previous_headings":"","what":"Study Objective","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"study investigates whether donor KIR genotype influences reactivation CMV T-cell replete, matched sibling donor reduced-intensity conditioning allogeneic HSCT.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/cytomegalovirus.html","id":"subjects-and-variables","dir":"Reference","previous_headings":"","what":"Subjects and Variables","title":"Retrospective Cohort Study of the Effects of Donor KIR genotype on the reactivation of cytomegalovirus (CMV) after myeloablative allogeneic hematopoietic stem cell transplant.\n — cytomegalovirus","text":"study included 64 consecutive patients underwent T-cell replete, matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant January 16, 2000 April 24, 2007 Cleveland Clinic. Human leucocyte antigen (HLA) typing donors recipients performed allow assessment killer immunoglobulin-like receptor ligands (KIRs). allow comparison previous studies, donors categorized 1-4 5-6 activating killer immunoglobulin-like receptor genes (aKIRs). CMV reactivation defined detection cytomegalovirus DNA blood; lower detection limit assay 600 copies/mL. initial population consisted 865 men undergone radical prostatectomy received transfusion within 30 days surgical procedure Cleveland Clinic available PSA follow-data. patients, 110 excluded analysis received combination allogeneic autologous blood products. remaining 755 patients, 405 (54%) received solely allogeneic 350 patients (46%) received solely autologous RBC units. 405 patients received allogeneic RBC transfusion, 89 excluded transfused RBC age distribution included one terciles. Thus, dataset consists 316 patients received solely allogeneic blood products classified RBC age exposure group.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/diabetes.html","id":null,"dir":"Reference","previous_headings":"","what":"Diabetes Prediction Dataset from the Pima Indian Tribe and the NIDDK — diabetes","title":"Diabetes Prediction Dataset from the Pima Indian Tribe and the NIDDK — diabetes","text":"dataset collected funding National Institute Diabetes Digestive Kidney Diseases (NIDDK). Pima Indian tribe located near Phoenix, Arizona (USA) high rate type 2 diabetes. dataset includes number variables predictive diabetes, outcome type 2 diabetes diagnosis within 5 years initial measurements. dataset includes females least 21 years age, Pima Indian heritage, least 5 years followup longitudinal study diabetes.  Pima Indian tribe participated longitudinal diabetes study since 1965 high incidence rate diabetes. community resident 5 years age asked undergo standardized examination every two years, included oral glucose tolerance test. Diabetes diagnosed according World Health Organization Criteria; , 2 hour post-load plasma glucose least 200 mg/dl survey examination Indian Health Service Hospital serving community found glucose concentration least 200 mg/dl course routine medical care.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/diabetes.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Diabetes Prediction Dataset from the Pima Indian Tribe and the NIDDK — diabetes","text":"","code":"diabetes"},{"path":"https://higgi13425.github.io/medicaldata/reference/diabetes.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Diabetes Prediction Dataset from the Pima Indian Tribe and the NIDDK — diabetes","text":"data frame 768 observations 9 variables, significant missing data predictor variables. pregnancy_num number pregnancies 0 17; type: double glucose_mg-dl Plasma glucose concentration 2 hours administration oral glucose tolerance test mg/deciliter, 44 199, 5 missing; type: double dbp_mm-hg diastolic blood pressure millimeters mercury (mm Hg), second number reported blood pressure, 24 122, 35 missing; type: double triceps_mm triceps skin fold thickness mm, measure subcutaneous fat, 7 99, 227 missing; type: double insulin_microiu-ml serum insulin 2 hours administration oral glucose tolerance test microIU per milliliter (IU international units), 14 846, 374 missing; type: double bmi body mass index, kg weight per meters height squared, 18.2 67.1, 11 missing; type: double pedigree diabetes pedigree score, points added additional relative diabetes, weighted closeness genetic relation participant, 0.78 2.42. Zero missing; type: double age Age years, 21 81, Zero missing; type: double diabetes_5y Diagnosis diabetes following 5 years - pos neg, 268 pos, Zero missing; type: factor","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/diabetes.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Diabetes Prediction Dataset from the Pima Indian Tribe and the NIDDK — diabetes","text":"data set provided funding National Institute Diabetes Digestive Kidney Diseases (NIDDK) dataset \"diabetes\". donor dataset UCI  Vincent Sigillito Johns Hopkins.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/diabetes.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Diabetes Prediction Dataset from the Pima Indian Tribe and the NIDDK — diabetes","text":"Type 2 diabetes mellitus (DM) associated obesity diet high sugars low vegetables. People type 2 DM become less sensitive insulin, glucose load, blood glucose insulin rise, glucose level fall quickly , leading sustained elevations glucose insulin. incidence type 2 DM rising many western cultures, increasingly unhealthy calorie rich diets become common. version dataset available UCI (University California-Irvine) Machine Learning Repository \"PimaIndiansDiabetes\". dataset recoded NA zero values likely missing variables glucose_mg-dl, insulin_mIU-mL, dbp_mm-hg, triceps_mm, bmi Friedrich Leisch. units predictor added variable names, several variables renamed clarity Peter Higgins. primary analysis task classify participant whether diabetes developed within 5 years data collection (diabetes_5y = pos), participant tested repeatedly negative diabetes next 5 years (diabetes_5y = neg).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/esoph_ca.html","id":null,"dir":"Reference","previous_headings":"","what":"esoph_ca: Esophageal Cancer dataset — esoph_ca","title":"esoph_ca: Esophageal Cancer dataset — esoph_ca","text":"Data case-control study esophageal cancer Ille-et-Vilaine, France, evaluating effects smoking alcohol incidence esophageal cancer. Smoking alcohol associated risk factors squamous cell cancer esophagus, rather adenocarcinoma esophagus, associated obesity esophageal reflux (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/esoph_ca.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"esoph_ca: Esophageal Cancer dataset — esoph_ca","text":"","code":"esoph_ca"},{"path":"https://higgi13425.github.io/medicaldata/reference/esoph_ca.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"esoph_ca: Esophageal Cancer dataset — esoph_ca","text":"data frame 88 rows 5 variables, 200 cases 975 controls. agegp 6 levels age: \"25-34\", \"35-44\", \"45-54\", \"55-64\", \"65-74\", \"75+\"; type: ordinal factor alcgp 4 levels alcohol consumption: \"0-39g/day\", \"40-79\", \"80-119\", \"120+\"; type: ordinal factor tobgp 4 levels tobacco consumption: \"0-9g/day\", \"10-19\", '20-29\", \"30+\"; type: ordinal factor ncases Number cases; type: integer ncontrols Number controls; type: integer","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/esoph_ca.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"esoph_ca: Esophageal Cancer dataset — esoph_ca","text":"Breslow, N. E. Day, N. E. (1980) Statistical Methods Cancer Research. Volume 1: Analysis Case-Control Studies. IARC Lyon / Oxford University Press. Originally base R datasets.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/esoph_ca.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"esoph_ca: Esophageal Cancer dataset — esoph_ca","text":"original base R dataset, though somewhat unclear origin. statistical textbook source clear, though clear original epidemiological papers esophageal cancer Ille-et-Vilaine referred dataset. original authors medical study credited base R dataset. several possible papers PubMed, none quite match dataset. Tuyns, AJ, et al., Bull Cancer, 1977;64(1):45-60, paper reports 778 controls, rather 975 found . 1975 paper group reported 718 cases (Int J Epidemiol, 1975 Mar;4(1):55-9.  doi: 10.1093/ije/4.1.55.). also another possible source - 1975 paper group, Usefulness population controls retrospective studies alcohol consumption. Experience case--control study esophageal cancer Ille-et-Vilaine, France, Journal Studies Alcohol, 39(1): 175-182 (1978), behind publisher paywall.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/esoph_ca.html","id":"figure-benign-fna-of-breast","dir":"Reference","previous_headings":"","what":"Figure 1 Benign FNA of Breast","title":"esoph_ca: Esophageal Cancer dataset — esoph_ca","text":"Benign fine needle aspirate (FNA) breast lesion. Notice regular size cells nuclei, organized orderly spacing. nuclei homogeneously dark visible nucleoli.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/esoph_ca.html","id":"figure-cancerous-fna-of-breast","dir":"Reference","previous_headings":"","what":"Figure 2 Cancerous FNA of Breast","title":"esoph_ca: Esophageal Cancer dataset — esoph_ca","text":"Malignant (cancerous) fine needle aspirate (FNA) breast lesion. Notice irregular size cells nuclei, disorganized seem growing . nuclei also less homogeneously dark granular, suggesting active transcription dark nucleoli within nucleus.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indo_rct.html","id":null,"dir":"Reference","previous_headings":"","what":"RCT of Indomethacin for Prevention of Post-ERCP Pancreatitis — indo_rct","title":"RCT of Indomethacin for Prevention of Post-ERCP Pancreatitis — indo_rct","text":"Results randomized, placebo-controlled, prospective 2-arm trial rectal indomethacin (100 mg) vs. placebo prevent post-ERCP pancreatitis 602 participants, reported Elmunzer, Higgins, et al. 2012 New England Journal Medicine (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indo_rct.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"RCT of Indomethacin for Prevention of Post-ERCP Pancreatitis — indo_rct","text":"","code":"indo_rct"},{"path":"https://higgi13425.github.io/medicaldata/reference/indo_rct.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"RCT of Indomethacin for Prevention of Post-ERCP Pancreatitis — indo_rct","text":"data frame 602 observations 33 variables id subject id, first integer indicates center, integer, range:1001-4003 site study site (center), factor, 1 = University Michigan, 2= Indiana University, 3 = University Kentucky, 4 = Case Western age age years, numeric, range:  19-90 risk risk score, numeric, range:   1-5.5 gender male female, factor, levels: 1_female, 2_male sod sphincter oddi dysfunction present, risk factor favoring post-ERCP pancreatitis, factor, levels: 0_no, 1_yes pep previous post-ERCP pancreatitis (PEP), risk factor future PEP, factor, levels: 0_no, 1_yes recpanc Recurrent Pancreatitis, risk factor future PEP, factor, levels: 0_no, 1_yes psphinc Pancreatic Sphincterotomy performed, risk factor PEP, factor, levels: 0_no, 1_yes precut sphincter pre-cut needed enter papilla, risk factor PEP, factor, levels: 0_no, 1_yes difcan Cannulation papilla difficult, risk factor PEP, factor, levels: 0_no, 1_yes pneudil Pneumatic dilation papilla performed, risk factor PEP, factor, levels: 0_no, 1_yes amp Ampullectomy performed dysplasia cancer, risk factor PEP, factor, levels: 0_no, 1_yes paninj Contrast injected pancreas procedure, risk factor PEP, factor, levels: 0_no, 1_yes acinar pancreas appeared acinarization imaging, risk factor PEP, factor, levels: 0_no, 1_yes brush Brushings taken pancreatic duct, possible risk factor favoring post-ERCP pancreatitis. factor, levels: 0_no, 1_yes asa81 Aspirin used dose 81 mg per day, may increase risk bleeding. factor, levels: 0_no, 1_yes asa325 Aspirin used dose 325 mg per day, may increase risk bleeding. factor, levels: 0_no, 1_yes asa Aspirin used (dose 325 mg per day(dose), may increase risk bleeding. factor, levels: 0_no, 1_yes prophystent pancreatic duct stent placed end procedure per judgement endoscopist (often high-risk cases), potential protective effect PEP, factor, levels: 0_no, 1_yes therastent pancreatic duct stent placed order treat clinically significant narrowing pancreatic duct, potential protective effect PEP, factor, levels: 0_no, 1_yes pdstent pancreatic duct stent placed end procedure reason, potential protective effect PEP, factor, levels: 0_no, 1_yes sodsom Sphincter oddi manometry performed procedure SOD, risk factor PEP, factor, levels: 0_no, 1_yes bsphinc biliary sphincterotomy performed, risk factor PEP, factor, levels: 0_no, 1_yes bstent biliary stent placed relieve significant biliary obstruction, factor, levels: 0_no, 1_yes chole Choledocholithiasis (gallstones blocking biliary duct) present, factor, levels: 0_no, 1_yes pbmal Malignancy biliary duct pancreas found, factor, levels: 0_no, 1_yes train trainee participated ERCP, risk factor PEP, factor, levels: 0_no, 1_yes outcome outcome post-ercp pancreatitis, factor, levels: 0_no, 1_yes status outpatient status, factor, levels: 0_inpatient, 1_outpatient type Sphincter Oddi dysfunction type/level - higher numbers severe greater association PEP, factor, levels: 0_no SOC, 1_type 1, 2_type 2, 3_type 3 rx treatment arm, factor, levels: 0_placebo, 1_indomethacin bleed gastrointestinal bleed occurred (complication indomethacin therapy), factor, levels: 1. , 2. yes","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indo_rct.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"RCT of Indomethacin for Prevention of Post-ERCP Pancreatitis — indo_rct","text":"data set sourced authors 2012 manuscript New England Journal Medicine, entitled, Randomized Trial Rectal Indomethacin Prevent Post-ERCP Pancreatitis, pages 1414-1422 volume 366, April 12, 2012 edition, authored Elmunzer, BJ, Higgins PDR, et al. can find manuscript Indomethacin Prevent Post-ERCP Pancreatitis.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indo_rct.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"RCT of Indomethacin for Prevention of Post-ERCP Pancreatitis — indo_rct","text":"ERCP, endoscopic retrograde cholangio-pancreatogram, procedure performed threading endoscope mouth opening duodenum bile pancreatic digestive juices released intestine. ERCP helpful treating blockages flow bile (gallstones, cancer), diagnosing cancers pancreas, high rate complications (15-25%).  occurrence post-ERCP pancreatitis common feared complication, pancreatitis can result multisystem organ failure death, can occur ~ 16% ERCP procedures.  inflammatory cytokine storm can result procedural complication can quite severe. Several small randomized trials suggested anti-inflammatory NSAID therapies time ERCP reduce rate complication, rather small single-center studies, sufficiently convincing change practice.  Elmunzer, Higgins, colleagues performed meta-analysis small trials, suggested significant effect, indomethacin result 64% reduction post-ERCP pancreatitis.  investigators took possible -estimate effect (due publication bias), designed multicenter RCT planned 948 patients see reduction 50% placebo rate 10% indomethacin rate 5%. Two interim analyses performed, 400 600 patients enrolled, using alpha spending function. Data Safety Monitoring Board stopped study 602 participants enrolled significantly positive effect indomethacin, reduced post-ERCP pancreatitis 16% placebo group 9% indomethacin group.  can find manuscript Indomethacin Prevent Post-ERCP Pancreatitis.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indometh.html","id":null,"dir":"Reference","previous_headings":"","what":"Cohort Study of the Pharmacokinetics of Intravenous Indomethacin — indometh","title":"Cohort Study of the Pharmacokinetics of Intravenous Indomethacin — indometh","text":"Results Cohort Study Pharmacokinetics Intravenous Indomethacin, plasma concentrations time (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indometh.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Cohort Study of the Pharmacokinetics of Intravenous Indomethacin — indometh","text":"","code":"indometh"},{"path":"https://higgi13425.github.io/medicaldata/reference/indometh.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Cohort Study of the Pharmacokinetics of Intravenous Indomethacin — indometh","text":"data frame 66 observations 3 variables Subject subject id number participant; type: character time Time initial dose hours; type: double conc Concentration indomethacin plasma micrograms per milliliter' type: double","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indometh.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Cohort Study of the Pharmacokinetics of Intravenous Indomethacin — indometh","text":"Kwan, Breault, Umbenhauer, McMahon Duggan (1976) Kinetics Indomethacin absorption, elimination, enterohepatic circulation man. Pharmacokinetics Biopharmaceutics. 1976 Jun;4(3):255-80.  doi: 10.1007/BF01063617.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/indometh.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Cohort Study of the Pharmacokinetics of Intravenous Indomethacin — indometh","text":"data set contains data 6 healthy volunteer subjects participated pharmacokinetic study intravenous indomethacin. Indomethacin anti-inflammatory pain-relieving non-steroidal medication. can administered intravenous, oral, rectal suppository routes. indomethacin excreted bile reabsorbed intestine. phenomenon, called enterohepatic circulation, keeps drug around longer expected otherwise.  subject Study 1 (intravenous route) received single 50 mg dose radioactively labeled indomethacin (^14^-carbon-labeled, dose containing 25 microCuries radioactivity). Subjects received standard meal (one 8-oz can Metrecal, 8 oz whole milk, one medium-size apple) 30 rain prior medication 8 oz water every 2 hr throughout waking hours ensure adequate urine output. Blood samples taken frequent intervals first 8 hours dosing, quantity indomethacin plasma (well stool urine) time point measured micrograms per milliliter. data set contains plasma measurements Table 1 page 258 manuscript. paper published 1976 (post-Tuskegee reveal), mention ethics review, IRB review, consent healthy volunteers.  abstract original manuscript:  discernible quantitative differences biotransformation excretion indomethacin following oral, rectal, intravenous administration indomethacin-2-^14^C. Approximately 50% (range 24-115% n = 6) intravenous dose undergoes enterohepatic circulation. Thus bioavailability indomethacin systemic circulation may exceed administered dose. Relative intravenous dose, indomethacin 80 100% bioavailable suppositories capsules, respectively. Absorption /reabsorption appears rapid uniform rectal route. Recognition attributes biliary recycling also helps explain observed variability apparent plasma half-life, neglect requires alternative explanations anomalies disappearance rate plasma corresponding appearance rate urine.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/laryngoscope.html","id":null,"dir":"Reference","previous_headings":"","what":"Randomized, Comparison Trial of Video vs. Standard Laryngoscope — laryngoscope","title":"Randomized, Comparison Trial of Video vs. Standard Laryngoscope — laryngoscope","text":"data set contains 99 adult patients body mass index 30 50 kg/m2 required orotracheal intubation elective surgery. Patient demographics, airway assessment data, intubation success rate, time intubation, ease intubation, occurrence complications recorded. dataset cleaned complete. outliers data problems (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/laryngoscope.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Randomized, Comparison Trial of Video vs. Standard Laryngoscope — laryngoscope","text":"","code":"laryngoscope"},{"path":"https://higgi13425.github.io/medicaldata/reference/laryngoscope.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Randomized, Comparison Trial of Video vs. Standard Laryngoscope — laryngoscope","text":"data frame 99 observations 22 variables age Age (years), numeric, range: 20-77 gender Gender, numeric, 0 = female; 1 = male asa American Society Anesthesiologists physical status(1-4), range:  2-4 BMI Body Mass Index (kg/m^2), numeric, range: 31-61 Mallampati Mallampati score predicting ease intubation 1 = Full visibility tonsils, uvula soft palate (easy intubation); 2 = Visibility hard soft palate, upper portion tonsils uvula; 3 = Soft hard palate base uvula visible; 4 = Hard Palate visible (difficult intubation), numeric, range:  1-4 Randomization Laryngoscope randomized, numeric, range:  0 = Standard Macintosh #4, 1 = AWS Pentaz Video attempt1_time First intubation attempt time (seconds), numeric, range:  9-113 attempt1_S_F Successful intubation first attempt, numeric, 0 = , 1 = yes attempt2_time Second intubation attempt time (seconds), numeric, range: 11- 60 attempt2_assigned_method Second intubation attempt made assigned laryngoscope, numeric, 0 = , 1 = yes attempt2_S_F Successful intubation second attempt, numeric, 0 = , 1 = yes, numeric, range:  0 = , 1 = yes attempt3_time Third intubation attempt time (seconds), numeric, range: 15- 30 attempt3_assigned_method Third intubation attempt made assigned laryngoscope, numeric, 0 = , 1 = yes attempt3_S_F Successful intubation third attempt, numeric, 0 = , 1 = yes, numeric, range:  1-1 attempts Number intubation attempts, numeric, range:  1-3 failures Number intubation failures, numeric, range:  0-2 total_intubation_time Total Intubation time (second), numeric, range:  9-100 intubation_overall_S_F Overall successful intubation, numeric, 0 = , 1 = yes bleeding Bleeding (trace), numeric, 0 = , 1 = yes ease Ease tracheal intubation, 0 = extremely easy 100 = extremely difficult, numeric, range:  0-100 sore_throat Severity postoperative sore throat, 0 = none; 1 = mild; 2 = moderate; 3 = severe, numeric, range:  0-  3 view Cormack-Lehane grade glottic view 0 = \"good\" Cormack- Lehane grade 1 2; 1 = \"good\" Cormack-Lehane grade 3 4,  numeric, range:  0-  1","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/laryngoscope.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Randomized, Comparison Trial of Video vs. Standard Laryngoscope — laryngoscope","text":"data study Abdallah et al. Randomized Comparison Pentax AWS Video Laryngoscope Macintosh Laryngoscope Morbidly Obese Patients. Anesthesia Analgesia 2011; 113: 1082-7.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/laryngoscope.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Randomized, Comparison Trial of Video vs. Standard Laryngoscope — laryngoscope","text":"Laryngoscope dataset contributed Dr. Amy Nowacki, Associate Professor, Cleveland Clinic. Please refer resource : Amy S. Nowacki, 'Laryngoscope Dataset', TSHS Resources Portal (2017). Available https://www.causeweb.org/tshs/laryngoscope/.  Difficult failed tracheal intubations among principal causes anesthetic-related mortality morbidity. good laryngeal view facilitates successful tracheal intubation, new technologies introduced improve visualization. Video laryngoscopes, example, often use miniature cameras facilitate visualization laryngeal inlet need align oral, pharyngeal, tracheal axes. Pentax AWS novel video laryngoscope, available Japan since 2006, designed facilitate intubation providing video image glottis. incorporates miniature video camera battery-powered, built-LCD monitor. disposable blade attached base system. Incorporation LCD display makes possible view glottis simultaneously insertion endotracheal tube (ETT). regard, differs video laryngoscope designs use external monitors. Pentax AWS also differs side channel positions guides ETT. Reports suggest Pentax AWS can help intubate, randomized data remain sparse.cr study tested hypothesis intubation Pentax AWS easier faster standard Macintosh laryngoscope #4 blade.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/licorice_gargle.html","id":null,"dir":"Reference","previous_headings":"","what":"Randomized, Controlled Trial of Licorice Gargle before Intubation for Elective Thoracic Surgery — licorice_gargle","title":"Randomized, Controlled Trial of Licorice Gargle before Intubation for Elective Thoracic Surgery — licorice_gargle","text":"study enrolled 236 adult patients undergoing elective thoracic surgery requiring double-lumen endotracheal tube. Gender, physical status, BMI, age, Mallampati score, smoking status, preoperative pain, surgery size, intervention outcomes (cough, sore throat pain swallowing various time points) provided. dataset cleaned complete (missing outcomes 2 patients). outliers data problems (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/licorice_gargle.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Randomized, Controlled Trial of Licorice Gargle before Intubation for Elective Thoracic Surgery — licorice_gargle","text":"","code":"licorice_gargle"},{"path":"https://higgi13425.github.io/medicaldata/reference/licorice_gargle.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Randomized, Controlled Trial of Licorice Gargle before Intubation for Elective Thoracic Surgery — licorice_gargle","text":"data frame 235 observations 19 variables preOp_gender Gender, numeric, 0 = Male; 1 = Female preOp_asa American Society Anesthesiologists physical status, numeric, 1 = normal healthy patient; 2 = patient mild systemic disease; 3 = patient severe systemic disease preOp_calcBMI Body mass index (kg/m^2), numeric, range:16-36 preOp_age Age (years), numeric, range:18-86 preOp_mallampati Mallampati score, 1 = easy intubate, 4= difficult intubation, numeric, 1 = soft palate, fauces, uvula, pillars visible; 2 = soft palate, fauces, uvula visible; 3 = soft palate, base uvula visible; 4 = soft palate visible preOp_smoking Smoking status, numeric, 1 = Current; 2 = Past; 3 = Never preOp_pain Preoperative pain, numeric, 0 = ; 1 = Yes treat Intervention, 0 = Sugar 5g; 1 = Licorice 0.5g intraOp_surgerySize Surgery size, numeric, 1 = Small (thoracoscopy); 2 = Medium (thoracotomy < 3 h); 3 = Large (thoracotomy > 3 h blood loss > 1000 mL) extubation_cough Amount coughing immediately extubation, numeric, 0 = cough; 1 = Mild; 2 = Moderate; 3 = Severe pacu30min_cough Amount coughing 30 minutes arrival PACU, numeric, 0 = cough; 1 = Mild; 2 = Moderate; 3 = Severe pacu30min_throatPain Sore throat pain score rest 30 minutes arrival PACU (11 point Likert scale, 0=pain, 10 = worst pain) pacu30min_swallowPain Sore throat pain score swallowing 30 minutes arrival PACU (11 point Likert scale, 0=pain, 10 = worst pain), numeric, range: 0-10 pacu90min_cough Amount coughing 90 minutes arrival PACU, numeric, 0 = cough; 1 = Mild; 2 = Moderate; 3 = Severe pacu90min_throatPain Sore throat pain score rest 90 minutes arrival PACU (11 point Likert scale, 0=pain, 10 = worst pain), numeric, range: 0-6) postOp4hour_cough Amount coughing 4 hours surgery, numeric, 0 = cough; 1 = Mild; 2 = Moderate; 3 = Severe, range: 0-2 postOp4hour_throatPain Sore throat pain score rest 4 hours surgery (11 point Likert scale, 0=pain, 10 = worst pain), numeric, range: 0-6), numeric, range: 0- 7 pod1am_cough Amount coughing first postoperative morning, 0 = cough; 1 = Mild; 2 = Moderate; 3 = Severe, numeric, range: 0- 3 pod1am_throatPain Sore throat pain score rest first postoperative morning (11 point Likert scale, 0=pain, 10 = worst pain), numeric, range: 0-6), numeric, range: 0- 6","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/licorice_gargle.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Randomized, Controlled Trial of Licorice Gargle before Intubation for Elective Thoracic Surgery — licorice_gargle","text":"data study Ruetzler et al. 'Randomized, Double-Blind Comparison Licorice Versus Sugar-Water Gargle Prevention Postoperative Sore Throat Postextubation Coughing'. Anesth Analg 2013; 117: 614 – 21.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/licorice_gargle.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Randomized, Controlled Trial of Licorice Gargle before Intubation for Elective Thoracic Surgery — licorice_gargle","text":"Licorice Gargle dataset contributed Dr. Amy Nowacki, Associate Professor, Cleveland Clinic. Please refer resource : Amy S. Nowacki, 'Licorice Gargle Dataset', TSHS Resources Portal (2017). Available https://www.causeweb.org/tshs/licorice-gargle/. Postoperative sore throat common annoying complication endotracheal intubation. Intubation double-lumen tubes, much larger conventional single-lumen tubes, especially likely provoke sore throats, reported incidence 90%. Presumably, postoperative sore throats consequence local tissue trauma, due laryngoscopy /endotracheal intubation, leading inflammation pharyngeal mucosa. Nonpharmacological methods preventing intubation-related sore throat include using smaller-sized endotracheal tubes, lubricating endotracheal tube water-soluble jelly, careful airway instrumentation examples. Pharmacological measures attenuating postoperative sore throats include inhalation beclomethasone fluticasone propionate; gargling azulene sulfonate, aspirin, ketamine; gargling spraying benzydamine hydrochloride endotracheal cuff example. approaches others listed, however, limitations variable success rates; thus none become established routine clinical use. Recently, study reported gargling licorice halves risk sore throat intubation conventional endotracheal tubes, based study just 40 patients. number active ingredients isolated licorice, including glycyrrhizin, liquilitin, liquiritigenin, glabridin. glycyrrhizin component reportedly anti-inflammatory antiallergic properties. Liquilitin liquiritigenin peripheral central antitussive properties. Glabridin significant antioxidant ulcer-healing properties, might help heal pharyngeal tracheal mucosa minor injuries often complicate laryngoscopy, intubation, endotracheal tube cuff inflation. study tested hypothesis gargling licorice solution immediately induction anesthesia prevents sore throat postextubation coughing patients intubated double-lumen tubes.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":null,"dir":"Reference","previous_headings":"","what":"Obstetrics and Periodontal Therapy Dataset  — opt","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"objective randomized controlled trial determine whether treatment maternal periodontal disease can reduce risk preterm birth low birth weight (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"","code":"opt"},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"data frame 823 observations 171 variables PID Participant ID, First digit indicates enrollment center (1 = NY, 2 = MN, 3 = KY, 4 = MS); Next 4 digits sequential; Sixth digit check digit; missing data, numeric, range: 100034-402477 Clinic Enrollment Center, factor, NY = Harlem Hospital, MN = Hennepin County Center; KY = University Kentucky; MS = University Mississippi Medical Center; missing data Group Randomized treatment assignment, factor, T = Intervention; C = Control; missing data Age Age participant baseline (years), numeric, range: 16-44 Black Black participant (self-identified), factor; Yes, White White participant (self-identified), factor; Yes, Nat.Native American participant, incl. Latin Americans aboriginal origin(self-identified), factor; Yes, Asian Asian participant (self-identified), factor; Yes, Hisp Hispanic participant (self-identified), factor; Yes, Education Education level participant, factor;  LT 8 yrs = Less 8 years; 8-12 yrs = 8 12 years; MT 12 yrs = 12 yrs; blank = Missing Public.Asstce Public Assistance: Whether government agency paid delivery, factor;  Yes, ; Hypertension Whether participant chronic hypertension baseline, factor; Yes, Diabetes Whether participant diabetes baseline (self-reported), factor; Yes, BL.Diab.Type Baseline Diabetes Type: Type diabetes, participants diabetes baseline (self-reported), factor; Type ; Type II; Blank = diabetes baseline (variable 13 = ) BMI NA, numeric, range: 15.000-68.0 Use.Tob Self-reported participant history tobacco use, factor; Yes, ; Blank = Missing BL.Cig.Day Self-reported number cigarettes per day tobacco use history, numeric, range: 1-30; Blank = Missing (variable 16= Yes blank) non-smoker (variable 16 = ) Use.Alc Self-reported participant history alcohol use, factor; Yes, ; Blank = Missing BL.Drks.Day , Blank = Missing (variable 18 = Yes blank) non-drinker (variable 18 = ) Drug.Add Self-reported participant history drug addiction, factor; Yes, ; Blank = Missing Prev.preg previous pregnancy, factor; Yes, ; missing data N.prev.preg Number previous pregnancies previous pregnancy, numeric, range:  1-11; Blank = Missing (variable 21 = Yes) previous pregnancies (variable 21 = ) Live.PTB Previous live preterm birth previous pregnancy, factor; Yes; = previous live preterm birth (variable 21 = Yes) previous pregnancies (variable 21 = ) .stillbirth Previous stillbirth, factor; Yes; = previous stillbirth (variable 21 = Yes) previous pregnancies (variable 21 = ) Spont.ab Previous spontaneous abortion, factor; Yes; ; Blank = Missing (variable 21 = Yes) previous pregnancies (variable 21 = ) Induced.ab Previous induced abortion, factor; Yes; ; Blank = Missing (variable 21 = Yes) previous pregnancies (variable 21 = ) .live.ptb.sb.sp.ab..ab previous live pre-term birth, stillbirth, spontaneous abortion, induced abortion, factor; Yes; = live pre-term birth/stillbirth/abortion (variable 21 = Yes) previous pregnancies (variable 21 = ) N.living.kids Number living children subject baseline, numeric, range: 0-9; Blank = Missing (variable 21 = Yes) previous pregnancies (variable 21 = ) Tx.comp. Whether treatment plans completed participants treatment group, factor, Yes = Completed; = completed; Und = therapy (unknown whether completed); Blank = Withdrew treatment (variable 3 = T) periodontal therapy (variable 3 = C) Local.anes Whether local anesthetic used periodontal therapy participants treatment group, factor, Yes; = local anesthetic used withdrew treatment (variable 3 = T); Blank = periodontal therapy (variable 3 = C) Topical.Anest Whether topical anesthetic used periodontal therapy participants treatment group, factor, Yes; = topical anesthetic used withdrew treatment (variable 3 = T); Blank = periodontal therapy (variable 3 = C) Tx.time Total treatment time participants treatment group (hours), numeric, range: 0.117-5.8; Blank = Withdrew treatment (variable 3 = T variable 29 = blank) periodontal therapy (variable 3 = C) EDC.necessary. Whether patient required1 essential dental care (EDC), factor, Yes; ; Blank = Missing Completed.EDC patient complete EDC 20 weeks gestational age?, factor, Yes; ; Blank = Missing N.extractions Number teeth extracted EDC, numeric, range: 0-20; Blank = Missing N.perm.restorations Number permanent restorations carried part EDC, numeric, range: 0-18; Blank = Missing N.qualifying.teeth Number teeth meeting OPT (Obstetrics Periodontal Therapy Study) criteria periodontal disease baseline, numeric, range: 3.000-28.0 BL.GE Whole-mouth average gingival index baseline, numeric, range: 0.429-3.0, Silness-Lowe Gingival Index: Higher value indicates severe inflammation; 0 = Normal gingiva; missing data BL..BOP Percentage sites bleeding probing baseline, numeric, range:33.951-100.0 BL.PD.avg Whole-mouth average pocket depth baseline (mm), numeric, range: 1.851-7.0 BL..PD.4 Percentage sites pocket depth greater equal 4mm baseline, numeric, range: 3.571-99.2 BL..PD.5 Percentage sites pocket depth greater equal 5mm baseline, numeric, range:  0-91.7 BL.CAL.avg Whole-mouth average clinical attachment level baseline (mm), numeric, range: 0.185-5.1 BL..CAL.2 Percentage sites clinical attachment level greater equal 2 mm baseline, numeric, range: 2.381-100.0 BL..CAL.3 Percentage site clinical attachment level greater equal 3 mm baseline, numeric, range: 0-94.9 BL.Calc.Whole-mouth average calculus index baseline, Simplified Oral Hygiene Index (OHI-S): Higher value indicates calculus; 0 = calculus present; numeric, range: 0-3.0 BL.Pl.Whole-mouth average plaque index baseline, Silness-Lowe Gingival Index:Higher value indicates severe inflammation, 0= normal gingiva, numeric, range: 0.056-3.0 V3.GE Whole-mouth average gingival index Visit 3, numeric, range:      0.030-3.0 V3..BOP Percentage sites bleeding probing Visit 3, numeric, range: 0.725-100.0, Blank = Missing V3.PD.avg Whole-mouth average pocket depth Visit 3 (mm), numeric, range: 1.601-5.5, Blank = Missing V3..PD.4 Percentage sites pocket depth greater equal 4mm Visit 3, numeric, range: 0-83.9, Blank = Missing V3..PD.5 Percentage sites pocket depth greater equal 5mm Visit 3, numeric, range: 0-77.4, Blank = Missing V3.CAL.avg Whole-mouth average clinical attachment level Visit 3 (mm), numeric, range: 0.036-3.9, Blank = Missing V3..CAL.2 Percentage sites clinical attachment level greater equal 2 mm visit 3, numeric, range: 0-97.8, Blank = Missing V3..CAL.3 Percentage sites clinical attachment level greater equal 3 mm visit 3, numeric, range: 0-85.7, Blank = Missing V3.Calc.Whole-mouth average calculus index visit 3, numeric, range:  0-2.6, Simplified Oral Hygiene Index (OHI-S): Higher value indicates calculus; 0 = calculus present; Blank = Missing V3.Pl.Whole-mouth average plaque index visit 3, numeric, range: 0-2.6, Silness-Lowe Plaque Index: Higher value indicates abundant plaque; 0 = plaque gingival area; Blank = Missing V5.GE Whole-mouth average gingival index visit 5, numeric, range: 0.190-2.7, Silness-Lowe Gingival Index: Higher value indicates severe inflammation; 0 = Normal gingiva; Blank = Missing V5..BOP Percentage sites bleeding probing visit 5, numeric, range: 3.571-100.0, Blank = Missing V5.PD.avg Whole-mouth average pocket depth visit 5, numeric, range: 1.536-5.4, Blank = Missing V5..PD.4 Percentage sites pocket depth greater equal 4mm Visit 5, numeric, range:  0-83, Blank = Missing V5..PD.5 Percentage sites pocket depth greater equal 5mm Visit 3, numeric, range: 0-75.6, Blank = Missing V5.CAL.avg Whole-mouth average clinical attachment level visit 5 (mm), numeric, range: 0.018-4.3, Blank = Missing V5..CAL.2 Percentage sites clinical attachment level greater equal 2 mm visit 5, numeric, range:  0.000-99.2, Blank = Missing V5..CAL.3 Percentage sites clinical attachment level greater equal 3 mm visit 5, numeric, range: 0.000-85.0, Blank = Missing V5.Calc.Whole-mouth average calculus index visit 5, numeric, range: 0.0-2.6, Simplified Oral Hygiene Index (OHI-S): Higher value indicates calculus; 0 = calculus present; Blank = Missing V5.Pl.Whole-mouth average plaque index visit 5, numeric, range: 0.0-2.5, Silness-Lowe Plaque Index: Higher value indicates abundant plaque; 0 = plaque gingival area; Blank = Missing N.PAL.sites Number sites attachment loss increased baseline greater equal 3 mm, numeric, range: 0-33, 0 = sites; Blank = Missing Birth.outcome Birth outcome, factor, Elective abortion; Live birth; Lost FU = Lost Follow-; Non-live birth = Stillbirth spontaneous abortion; missing data Preg.ended...37.wk Whether pregnancy ended gestational age 37 weeks (259 days), factor, Yes; ; Blank = Lost Follow-GA..outcome Gestational age end pregnancy, mother's last follow-visit lost follow-, numeric, range:  103-302 Birthweight Infant birth weight time birth, abstracted obstetrical records (grams), numeric, range:  101-5160, Blank = Missing Fetal.congenital.anomaly Fetal/congenital anomaly identified birth pregnancy?, factor, Yes; ; missing data Apgar1 Apgar score, summary newborn infant's 'Appearance, Pulse, Grimace, Activity, Respiration' 1 minute Score interpretation: less equal 3: Critically low 4-6: Fairly low greater equal 7: Normal, numeric, range: 0-10, Blank = Missing Apgar5 Apgar score 5 minutes, numeric, range: 0-10, Blank = Missing .SAE. Whether participant experienced serious adverse events (e.g. lost pregnancies) factor, Yes; ; missing data GA...1st.SAE Gestational age first SAE (serious adverse event), integer, range: 96-467, 259 = SAE (variable 76 must = ); missing data Bact.vag Whether mother bacterial vaginosis pregnancy, factor, Yes; ; Blank = Missing Gest.diab Whether mother gestational diabetes pregnancy, factor, Yes; ; Blank = Missing Oligo Whether mother oligohydramnios pregnancy, factor, Yes; ; Blank = Missing Polyhyd Whether mother polyhydramnios pregnancy, factor, Yes; ; Blank = Missing Gonorrhea Whether mother gonorrhea pregnancy, factor, Yes; ; Blank = Missing Chlamydia Whether mother chlamydia pregnancy, factor, Yes; ; Blank = Missing Strep.B Whether mother strep B colonization pregnancy, factor, Yes; ; Blank = Missing Traumatic.Inj Whether mother traumatic injury pregnancy, factor, Yes; ; Blank = Missing UTI Whether mother urinary tract infection pregnancy, factor, Yes; ; Blank = Missing Pre.eclamp Whether mother pre-eclampsia, pregnancy condition characterized high blood pressure associated fetal growth restriction pregnancy, factor, Yes; ; Blank = Missing Mom.HIV.status HIV status mother pregnancy, factor, Yes = HIV-positive; = HIV-negative unknown (question answered HIV status delivery recorded); Blank = Missing (question answered) BL.Anti.inf participant report use antiinflammatory medication less 6 months baseline?, integer,  0 = ; 1 = Yes; missing data BL.Cortico participant report use corticosteroids less 6 months baseline?, integer, 0 = ; 1 = Yes; missing data BL.Antibio participant report use antibiotics less 6 months baseline?, integer,  0 = ; 1 = Yes; missing data BL.Bac.vag participant report use bacterial vaginitis treatments less 6 months baseline?, integer, 0 = ; 1 = Yes; missing data V3.Anti.inf participant report use antiinflammatory medication baseline visit 3?,integer, 0 = ; 1 = Yes; missing data V3.Cortico participant report use corticosteroids baseline visit 3?, integer, 0 = ; 1 = Yes; missing data V3.Antibio participant report use antibiotics baseline visit 3?, integer, 0 = ; 1 = Yes; missing data V3.Bac.vag participant report use bacterial vaginitis treatments baseline visit 3?, integer, 0 = ; 1 = Yes; missing data V5.Anti.inf participant report use antiinflammatory medication visit 3 visit 5?, integer, 0 = ; 1 = Yes; missing data V5.Cortico participant report use corticosteroids visit 3 visit 5?, integer, 0 = ; 1 = Yes; missing data V5.Antibio participant report use antibiotics visit 3 visit 5?, integer, 0 = ; 1 = Yes; missing data V5.Bac.vag participant report use bacterial vaginitis treatments visit 3 visit 5?, integer, 0 = ; 1 = Yes; missing data X..Vis.Att Visit attendance: Number study visits attended baseline, integer, Range: 0-5 X..Vis.Elig Number visits participant eligible (become ineligible miscarriage early delivery), integer, Range: 0-5 X1st.Miss.Vis First missed visit. one missed baseline visit, variable takes values 2, 3, 4, 5, 6, 100 (eligible visits missed), integer, Range: 2-6, 100 OAA1 Serum IgG (immunoglobulin) antibodies . actinomycetemcomitans baseline, factor (actually numeric missing), dot(.) = Missing OCR1 Serum IgG (immunoglobulin) antibodies C. rectus baseline, factor (actually numeric missing), dot(.) = Missing OFN1 Serum IgG (immunoglobulin) antibodies F. nucleatum baseline, factor (actually numeric missing), dot(.) = Missing OPG1 Serum IgG (immunoglobulin) antibodies P. gingivalis baseline, factor (actually numeric missing), dot(.) = Missing OPI1 Serum IgG (immunoglobulin) antibodies P. intermedia baseline, factor (actually numeric missing), dot(.) = Missing OTD1 Serum IgG (immunoglobulin) antibodies T. denticola baseline, factor (actually numeric missing), dot(.) = Missing OTF1 Serum IgG (immunoglobulin) antibodies T. forsythus baseline, factor (actually numeric missing), dot(.) = Missing OCRP1 Serum measure C-reactive protein (CRP) baseline, factor (actually numeric missing), dot(.) = Missing O1B1 Serum measure Interleukin(IL)-1b baseline, factor (actually numeric missing), dot(.) = Missing O61 Serum measure Interleukin(IL)-6 baseline, factor (actually numeric missing), dot(.) = Missing O81 Serum measure forInterleukin(IL)-8 baseline, factor (actually numeric missing), dot(.) = Missing OPGE21 Serum measure Prostaglandin E2 baseline, factor (actually numeric missing), dot(.) = Missing OTNF1 Serum measure tumor necrosis factor (TNF)-alpha baseline, factor (actually numeric missing), dot(.) = Missing OMMP91 Serum measure gelatinase (MMP9) baseline, factor (actually numeric missing), dot(.) = Missing ETXU_CAT1 Serum endotoxin level baseline, factor (actually numeric missing), dot(.) = Missing OFIBRIN1 Serum measure fibrinogen baseline, factor (actually numeric missing), dot(.) = Missing OAA5 Serum IgG (immunoglobulin) antibodies . actinomycetemcomitans visit 5, factor (actually numeric missing), dot(.) = Missing OCR5 Serum IgG (immunoglobulin) antibodies C. rectus visit 5, factor (actually numeric missing), dot(.) = Missing OFN5 Serum IgG (immunoglobulin) antibodies F. nucleatum visit 5, factor (actually numeric missing), dot(.) = Missing OPG5 Serum IgG (immunoglobulin) antibodies P. gingivalis visit 5, factor (actually numeric missing), dot(.) = Missing OPI5 Serum IgG (immunoglobulin) antibodies P. intermedia visit 5, factor (actually numeric missing), dot(.) = Missing OTD5 Serum IgG (immunoglobulin) antibodies T. denticola visit 5, factor (actually numeric missing), dot(.) = Missing OTF5 Serum IgG (immunoglobulin) antibodies T. forsythus visit 5, factor (actually numeric missing), dot(.) = Missing OCRP5 Serum measure C-reactive protein (CRP) visit 5, factor (actually numeric missing), dot(.) = Missing O1B5 Serum measure Interleukin(IL)-1b visit 5, factor (actually numeric missing), dot(.) = Missing O65 Serum measure forInterleukin(IL)-6 visit 5, factor (actually numeric missing), dot(.) = Missing O85 Serum measure forInterleukin(IL)-8 visit 5, factor (actually numeric missing), dot(.) = Missing OPGE25 Serum measure Prostaglandin E2 visit 5, factor (actually numeric missing), dot(.) = Missing OTNF5 Serum measure tumor necrosis factor (TNF)-alpha visit 5, factor (actually numeric missing), dot(.) = Missing OMMP95 Serum measure gelatinase (MMP9) visit 5, factor (actually numeric missing), dot(.) = Missing ETXU_CAT5 Serum endotoxin level visit 5, factor (actually numeric missing), dot(.) = Missing OFIBRIN5 Serum measure fibrinogen visit 5, factor (actually numeric missing), dot(.) = Missing BL.DNA Total amount bacterial DNA extracted plaque measure total bacterial concentration baseline (ng/mL), numeric, range: 0-5750.0 BL.Univ Count bacteria detected universal primer baseline, numeric, range: 1,890,000-1,070,000,000, Blank = Missing BL.AA Count . actinomycetemcomitans bacteria baseline, numeric, range:  0-7,970,000, Blank = Missing BL.PG Count P. gingivalis bacteria baseline, numeric, range:  0-167,000,000, Blank = Missing BL.TD Count T. denticola bacteria baseline, numeric, range:  0-50,500,000, Blank = Missing BL.TF Count T. forsythus bacteria baseline, numeric, range:  0-40,200,000, Blank = Missing BL.PI Count P. intermedia bacteria baseline, numeric, range:  0-87,500,000, Blank = Missing BL.CR Count C. rectus bacteria baseline, numeric, range:  0-32,600,000, Blank = Missing BL.FN Count F. nucleatum bacteria baseline, numeric, range:  67,300- 152,000,000, Blank = Missing BL.S7 Sum 7 species-specific bacterial counts (variables 138-144) baseline, rounded 3 significant figures, numeric, range:  87,000-391,000,000, Blank = Missing V5.DNA Total amount bacterial DNA extracted plaque measure total bacterial concentration visit 5 (ng/mL), numeric, range: 0-5750.0 V5.Univ Count bacteria detected universal primer visit 5, numeric, range: 1,890,000-1,070,000,000, Blank = Missing V5.AA Count . actinomycetemcomitans bacteria visit 5, numeric, range:  0-40,200,000, Blank = Missing V5.PG Count P. gingivalis bacteria visit 5, numeric, range:  0-40,200,000, Blank = Missing V5.TD Count T. forsythus bacteria visit 5, numeric, range:  0-40,200,000, Blank = Missing V5.TF Count T. forsythus bacteria visit 5, numeric, range:  0-40,200,000, Blank = Missing V5.PI Count P. intermedia bacteria visit 5, numeric, range:  0-87,500,000, Blank = Missing V5.CR Count C. rectus bacteria visit 5, numeric, range:  0-32,600,000, Blank = Missing V5.FN Count F. nucleatum bacteria visit 5, numeric, range:  67,300- 152,000,000, Blank = Missing V5.S7 Sum 7 species-specific bacterial counts (variables 138-144) visit 5, rounded 3 significant figures, numeric, range:  87,000-391,000,000, Blank = Missing BL..AA Percent . actinomycetemcomitans total DNA (variable 146) baseline, numeric, range:  0-8.9, Blank = Missing BL..PG Percent P. gingivalis total DNA baseline, numeric, range:  0-37.3, Blank = Missing BL..TD Percent T. denticola total DNA baseline, numeric, range:  0-13.2, Blank = Missing BL..TF Percent T. forsythus total DNA baseline, numeric, range:  0-17.7, Blank = Missing BL..PI Percent P. intermedia total DNA baseline, numeric, range:  0-46.3, Blank = Missing BL..CR Percent C. rectus total DNA baseline, numeric, range:  0-10.5, Blank = Missing BL..FN Percent F. nucleatum total DNA baseline, numeric, range: 0.330-63.2, Blank = Missing BL..S7 Sum percents 7 species (AA, PG, TD, TF, PI, CR, FN) baseline, numeric, range: 0.420-86.3, Blank = Missing V5..AA Percent . actinomycetemcomitans total DNA visit 5, numeric, range: 0-16.1, Blank = Missing V5..PG Percent P. gingivalis total DNA visit 5, numeric, range: 0-59.7, Blank = Missing V5..TD Percent T. denticola total DNA visit 5, numeric, range: 0-20.5, Blank = Missing V5..TF Percent T. forsythus total DNA visit 5, numeric, range: 0-19.3, Blank = Missing V5..PI Percent P. intermedia total DNA visit 5, numeric, range: 0-40.7, Blank = Missing V5..CR Percent C. rectus total DNA visit 5, numeric, range: 0-14.6, Blank = Missing V5..FN Percent F. nucleatum total DNA visit 5, numeric, range: 0-49.9, Blank = Missing V5..S7 Sum percents 7 species (AA, PG, TD, TF, PI, CR, FN) visit 5, numeric, range: 2.560-80.8, Blank = Missing","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"Michalowicz et al., 'Treatment periodontal disease risk preterm birth', N Engl J Med 2006; 355:1885-1894. DOI: 10.1056/NEJMoa062249","code":""},{"path":[]},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"background-","dir":"Reference","previous_headings":"","what":"Background:","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"Randomized Clinical Trial Effect Treatment Maternal Periodontal Disease Can Reduce Preterm Birth Risk. Maternal periodontal disease linked observational studies preterm birth (< 37 weeks) low birth weight (< 2500 g) outcomes. Obstetrics Periodontal Therapy study multi-center randomized trial evaluating effect nonsurgical periodontal treatment intervention preterm birth, comparing outcomes women treated 21 weeks gestation (treatment) treated delivery (control).  Preterm birth, defined delivery 37 weeks gestation, growing problem. cases, preterm birth can lead infant death; others, consequences may include neurodevelopmental disabilities, cognitive impairment, /respiratory disorders child. Many risk factors preterm birth already identified, including maternal age, drug use, diabetes. However, factors exhibited half preterm birth mothers, highlighting need expand understanding contributes preterm birth risk. Several observational studies suggested association maternal periodontal disease preterm birth. Periodontal disease inflammatory condition characterized destruction tissue /bone around teeth. major component periodontal disease oral colonization gram-negative bacteria; systemic release cytokines /lipopolysaccharides bacteria may impact fetal condition. Inoculation periodontal pathogen P. gingivalis pregnant animals dose-dependent effect birth weight preterm birth signaling, causal link shown humans, associations. Though definitive, possibility significant relationship raises question whether treatment maternal periodontal disease can decrease preterm birth risk.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"participants-","dir":"Reference","previous_headings":"","what":"Participants:","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"823 participants enrolled 4 centers underwent stratified randomization, resulting 413 women assigned treatment group 410 control. participants 13-16 weeks pregnant time randomization (baseline/visit 1) went attend monthly follow-visits defined visits 2, 3, 4, 5 corresponding gestational age ranges 17-20, 21-24, 25-28, 29-32 weeks.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"treatment-","dir":"Reference","previous_headings":"","what":"Treatment:","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"treatment group received periodontal treatment, oral hygiene instruction, tooth polishing follow-ups, assigned control underwent brief oral exams. Data collection occurred visits 1 (baseline), 3, 5. primary outcome interest gestational age end pregnancy. Additional outcomes include birthweight, clinical measures periodontal disease, various microbiological immunological outcomes.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"analysis-","dir":"Reference","previous_headings":"","what":"Analysis:","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"Statistical analyses carried intent--treat basis. Gestational age can thought 'time end pregnancy,' certain survival analysis methods appropriate. study used log-rank test stratified center compare time end pregnancy treatment control groups. semiparametric proportional hazards model also used purpose incorporated maternal risk factors predictors. study's main analyses, gestational age censored 37 weeks (259 days) interest extending pregnancies otherwise end pre-term, extending pregnancies generally. Though used study , logistic regression another method applied: example, gestational age, dichotomized 'preterm' 'preterm' according gestational age cutoff, birthweight dichotomized 'low' 'high' 2500 g cutoff (2500 g keeping World Health Organization's definition low birth weight). Changes clinical measures periodontal disease baseline visits 3 5 analyzed using mixed effects linear models. dataset also features number baseline characteristics, compared treatment control groups via Student t-tests, Wilcoxon rank sum tests, Fisher's exact tests Pearson's chi-square tests, appropriate.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/opt.html","id":"publishing-","dir":"Reference","previous_headings":"","what":"Publishing:","title":"Obstetrics and Periodontal Therapy Dataset  — opt","text":"nonsurgical periodontal treatment involving scaling root planing induced significant improvements periodontal health. study however find significant relation periodontal treatment preterm birth risk. results study published 2006 Michalowicz et al., 'Treatment periodontal disease risk preterm birth', New England Journal Medicine. Obstetrics Periodontal Therapy Dataset contains data used study. obstetrics periodontal therapy dataset contributed Dr. Ann Brearley, Assistant Professor, Division Biostatistics, School Public Health, University Minnesota colleagues. Please refer resource : Meredith Hyun, James S. Hodges Ann M. Brearley, 'Obstetrics Periodontal Therapy Dataset', TSHS Resources Portal (2019). Available https://www.causeweb.org/tshs/obstetrics--periodontal-therapy/.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/polyps.html","id":null,"dir":"Reference","previous_headings":"","what":"RCT of Sulindac for Polyp Prevention in Familial Adenomatous Polyposis — polyps","title":"RCT of Sulindac for Polyp Prevention in Familial Adenomatous Polyposis — polyps","text":"Results randomized, placebo-controlled trial sulindac reduction colonic polyps Familial Adenomatous Polyposis  (FAP) (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/polyps.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"RCT of Sulindac for Polyp Prevention in Familial Adenomatous Polyposis — polyps","text":"","code":"polyps"},{"path":"https://higgi13425.github.io/medicaldata/reference/polyps.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"RCT of Sulindac for Polyp Prevention in Familial Adenomatous Polyposis — polyps","text":"data frame 22 observations 7 variables participant_id id number participant; type: character sex participant sex, levels: female, male; type: factor age age years; type: numeric baseline number colonic polyps baseline; type: numeric treatment treatment assignment, levels: sulindac, placebo; type: factor number3m number colonic polyps 3 months; type: numeric number12m number colonic polyps 12 months; type: numeric","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/polyps.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"RCT of Sulindac for Polyp Prevention in Familial Adenomatous Polyposis — polyps","text":"data set study published 1993 New England Journal Medicine, F. M. Giardiello, S. R. Hamilton, . J. Krush, S. Piantadosi, L. M. Hylind, P. Celano, S. V. Booker, C. R. Robinson G. J. . Offerhaus (1993), Treatment colonic rectal adenomas sulindac familial adenomatous polyposis. New England Journal Medicine, 328(18), 1313-1316. dataset derived improved upon HSAUR package.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/polyps.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"RCT of Sulindac for Polyp Prevention in Familial Adenomatous Polyposis — polyps","text":"FAP inherited condition caused mutations APC  (Adenomatous Polyposis Coli) gene leads early frequent formation precancerous polyps colon young age, invariably leads development colon cancer young age.   Early, frequent surveillance colonoscopy polyp removal helpful, study examined whether beneficial effect preventive medical therapy nonsteroidal pain reliever, sulindac, versus placebo RCT vs placebo 22 participants, polyp number measured (via colonoscopy) baseline, 3 months, 12 months starting study drug. Note one subject return 12 month colonoscopy.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/scurvy.html","id":null,"dir":"Reference","previous_headings":"","what":"Randomized Trial of Six Therapies for Scurvy — scurvy","title":"Randomized Trial of Six Therapies for Scurvy — scurvy","text":"Results randomized, 6-arm comparator-controlled trial 6 interventions treat scurvy 12 disabled seamen, reported James Lind 1757 (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/scurvy.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Randomized Trial of Six Therapies for Scurvy — scurvy","text":"","code":"scurvy"},{"path":"https://higgi13425.github.io/medicaldata/reference/scurvy.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Randomized Trial of Six Therapies for Scurvy — scurvy","text":"data frame 12 observations 8 variables study_id invented id number participant; type: character treatment assigned treatment, levels: cider, dilute_sulfuric_acid, vinegar, sea_water, citrus, purgative_mixture; type: factor dosing_regimen_for_scurvy details daily dosing schedule; type: character gum_rot_d6 rating symptom rotting gums; type: factor, levels: 0=none, 1=mild, 2=moderate, 3=severe skin_sores_d6 rating symptom skin sores; type: factor, levels: 0=none, 1=mild, 2=moderate, 3=severe weakness_of_the_knees_d6 rating symptom weakness knees (ability stand); type: factor, levels: 0=none, 1=mild, 2=moderate, 3=severe lassitude_d6 rating symptom lassitude (generalized weakness); type: factor, levels: 0=none, 1=mild, 2=moderate, 3=severe fit_for_duty_d6 dichotomous fitness duty seaman; type: factor: 0_no, 1_yes","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/scurvy.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Randomized Trial of Six Therapies for Scurvy — scurvy","text":"data set faithfully reconstructed report published 1757 Treatise Scurvy 3 Parts, James Lind, pp. 149-153, can find scan source document can read Google Books .","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/scurvy.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Randomized Trial of Six Therapies for Scurvy — scurvy","text":"Scurvy common affliction seamen long voyages, leading mouth sores, skin lesions, weakness knees, lassitude. Scurvy fatal long voyages. James Lind reported treatment 12 seamen scurvy 1757, Treatise Scurvy Three Parts. 476 page bloviation can found scanned Google Books website Treatise Scurvy.    Pages 149-153 rare gem among can generously described 400+ pages evidence-free blathering, 4 pages may represent first report controlled clinical trial.  Lind ship's surgeon board HMS Salisbury, number scurvy-affected seamen disposal. Many remedies described advocated , anecdotal evidence. May 20, 1747, Lind decided try 6 available therapies disposal comparative study 12 affected seamen. selected 12 roughly similar severity, notable skin mouth sores, weakness knees, significant lassitude, making unfit duty. received standard shipboard diet gruel mutton broth, supplemented occasional biscuits puddings. treatment dietary supplement (including citrus fruits) medicinal.  data frame reconstructed Lind's account recorded 4 pages, estimates severity translated 4 point Likert scale (0-3) symptoms described chosen endpoint day 6. fanciful study_id variable added, along detailed descriptions dosing schedule treatment.  note, dispute whether truly first clinical trial, whether actually happened. See link historical debate.     Lind reported seamen treated 2 lemons orange daily best, followed treated cider. treated elixir vitriol improvement mouth sores. One imagines acidic substances (like dilute sulfuric acid, vinegar, cider, citrus fruits) might rather painful mouth sores. Unfortunately, burial 4 valuable pages data 476 pages noise, publication delay 10 years, Lind's half-hearted conclusions, meant took 1795 British Navy mandated daily limes seamen.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/smartpill.html","id":null,"dir":"Reference","previous_headings":"","what":"Prospective Cohort Study of Intestinal Transit using a SmartPill to Compare Trauma Patients to Healthy Volunteers — smartpill","title":"Prospective Cohort Study of Intestinal Transit using a SmartPill to Compare Trauma Patients to Healthy Volunteers — smartpill","text":"study evaluated gastric emptying, small bowel transit time, total intestinal transit time 8 critically ill trauma patients. data compared obtained 87 healthy volunteers separate trial. Data obtained motility capsule wirelessly transmitted pH, pressure, temperature recorder attached subject's abdomen. Transit times available almost patients, however, pH, pressure temperature data missing critically ill patients sparsely missing healthy volunteers (details available variable definitions)","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/smartpill.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Prospective Cohort Study of Intestinal Transit using a SmartPill to Compare Trauma Patients to Healthy Volunteers — smartpill","text":"","code":"smartpill"},{"path":"https://higgi13425.github.io/medicaldata/reference/smartpill.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Prospective Cohort Study of Intestinal Transit using a SmartPill to Compare Trauma Patients to Healthy Volunteers — smartpill","text":"data frame 95 obsrvations 22 variables Group Study group, numeric, 0 = Critically Ill Trama Patient, 1 = Healthy Volunteer Gender Gender, numeric, range: 0 = Female, 1 = Male Race Race, numeric, 1 = White, 2 = Black, 3 = Asian/Pacific Islander, 4 = Hispanic, 5 = Height Height (centimeters), numeric, range: 132.1-193.0 Weight Weight (kilograms), numeric, range:  44.9-127.0 Age Age (years), numeric, range:  18.0-72.0 GE.Time Gastric Emptying Time time ingestion gastric emptying (hours), numeric, range:   1.7-74.3 SB.Time Small Bowel Transit Time time gastric emptying ileocecal junction (hours), numeric, range:   1.8-13.8 C.Time Colonic Transit Time time ileocecal junction body exit (hours), numeric, range:   0.7-118.9 WG.Time Whole Gut Time time ingestion body exit (hours), numeric, range:   6.0-816.0 S.Contractions Stomach contractions counted peak amplitude contraction 10 mmHg 300 mmHg, numeric, range:  47.0-1665.0 S.Sum..Amplitudes Stomach sum amplitudes (mm Hg), numeric, range: 655.6-33800.3 S.Mean.Peak.Amplitude Stomach mean peak amplitude sum amplitudes divided number contractions (mm Hg), numeric, range:   4.6-43.4 S.Mean.pH Stomach mean pH average pH whole recording time stomach normal ~ 1.5-3.5, numeric, range:   1.5-5.9 SB.Contractions Small Bowel contractions counted peak amplitude contraction 10 mmHg 300 mmHg, numeric, range: 223.0-2375.0 SB.Sum..Amplitudes Small Bowel sum amplitudes (mm Hg), numeric, range:3899.4-41122.5 SB.Mean.Peak.Amplitude Small Bowell mean peak amplitude sum amplitudes divided number contractions (mm Hg), numeric, range:  15.0-27.9 SB.Mean.pH Small Bowel mean pH average pH whole recording time small bowel, normal ~ 6-7.4, numeric, range:   4.7-8.6 Colon.Contractions Colon contractions counted peak amplitude contraction 10 mmHg 300 mmHg, numeric, range:  41.0-2672.0 Colon.Sum..Amplitudes Colon sum amplitudes (mm Hg), numeric, range:1872.6-117707.5 C.Mean.Peak.Amplitude Colon mean peak amplitude sum amplitudes divided number contractions (mm Hg), numeric, range:  32.8-    64.2 C.Mean.pH Colon mean pH average pH whole recording time colon, normal ~ 5-7-6.7, numeric, range:   3.9-8.1","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/smartpill.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Prospective Cohort Study of Intestinal Transit using a SmartPill to Compare Trauma Patients to Healthy Volunteers — smartpill","text":"Rauch et al. 'Use Wireless Utility Capsule Determine Gastric Emptying Small Intestinal Transit Times Critically Ill Trauma Patients'. Journal Critical Care 2012; 27(5): 534.e7-534.e12.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/smartpill.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Prospective Cohort Study of Intestinal Transit using a SmartPill to Compare Trauma Patients to Healthy Volunteers — smartpill","text":"Smart Pill dataset contributed Dr. Amy Nowacki, Associate Professor, Cleveland Clinic. Please refer resource : Amy S. Nowacki, 'Smart Pill Dataset', TSHS Resources Portal (2017). Available https://www.causeweb.org/tshs/smart-pill/.  Delayed gastric emptying well-known problem critically ill patients associated feeding disturbances inadequate nutrition. However, evaluating gastrointestinal function remains challenging critically ill patients mechanically ventilated. Many tests practical accurate standardized, controlled conditions often fail critical care setting. example, consensus recommendations gastric emptying scintigraphy impractical intubated patients recommend low-fat, egg white meal imaging 0, 1, 2, 4 hours meal ingestion. Another test, lactulose hydrogen breath test, relies prompt bacterial breakdown lactulose colon; however, changes bacterial flora - presumably common critical care patients - can produce false transit times. 13C-octanoic acid breath test reported successful used bedside measure gastric emptying. However, manometry assesses upper gastrointestinal function, mainly esophagus, stomach, proximal small bowel. Finally, video capsule technology used determine small bowel transit time pathomorphology critically ill patients, although inadequate battery lifespan capsule (approximately 8-10 hours) prevent complete examination cases. alternative technique, wireless capsule technology, may useful evaluating gastrointestinal motility critical care patients. newly developed motility capsule assessing gastric emptying patients suspected gastroparesis available since 2006. wireless capsule transmits pH, pressure, temperature. study describes first use novel motility capsule compare gastric emptying small bowel transit times critically ill trauma patients intracranial hemorrhage times recorded previously healthy volunteers. Secondly, study compares critically ill patients volunteers whole-gut transit time.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/strep_tb.html","id":null,"dir":"Reference","previous_headings":"","what":"RCT of Streptomycin Therapy for Tuberculosis — strep_tb","title":"RCT of Streptomycin Therapy for Tuberculosis — strep_tb","text":"Results randomized, placebo-controlled, prospective 2-arm trial streptomycin 2 grams daily (arm A2) vs. placebo (arm A1) treat tuberculosis 107 young patients, reported Streptomycin Tuberculosis Trials Committee 1948 British Medical Journal (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/strep_tb.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"RCT of Streptomycin Therapy for Tuberculosis — strep_tb","text":"","code":"strep_tb"},{"path":"https://higgi13425.github.io/medicaldata/reference/strep_tb.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"RCT of Streptomycin Therapy for Tuberculosis — strep_tb","text":"data frame 107 observations 13 variables patient_id invented id number participant; type: character arm assigned treatment arm, Streptomycin Control; type: factor dose_strep_g grams, dose Streptomycin: numeric, 0, 1, 2 grams dose_PAS_g grams, dose PAS (Para-Amino-Salicylate): numeric, 5, 10, 20 grams. Note one intial study (study ) received PAS. added combination therapy studies B C, reported 1952. gender gender, dichotomous (1948); type: factor, levels: M = Male, F= Female baseline_condition Condition Patient Baseline, 3 levels, 1_Good, 2_Fair, 3_Poor; type: factor baseline_temp temperature baseline degrees fahrenheit celsius, categorized 4 levels (afebrile level apparently cases measured thermometer): factor, levels: 1_afebrile, 2_<99F/<37.2C, 3_99-99.9F/37.2-37.75C, 4_100F+/37.7C+ baseline_esr Erythrocyte Sedimentation Rate mm per hour, categorized 4 levels, 0-51+ mm per hour; type: factor, levels: 1_0-10, 2_11-20, 3_21-50, 4_51+ baseline_cavitation dichotomous presence cavitation baseline chest x-ray; type: factor: 0_no, 1_yes strep_resistance streptomycin resistance 6 months therapy, measured 0-100+ scale, categorized 3 levels - sensitive, moderate, resistant; type: factor: 1_sens_0-8, 2_mod_8-99, 3_resist_100+ radiologic_6m Likert score rating radiologic response chest x-ray 6 months; type: factor: 1_Death, 2_Considerable_deterioration, 3_Moderate_deterioration, 4_No_change, 5_Moderate_improvement, 6_Considerable_improvement rad_num Likert score numeric rating radiologic response chest x-ray 6 months; type: numeric: 1-6, Death Considerable Improvement improved Dichotomous outcome improvement (equal rad_num 5-6); type: logical, TRUE FALSE. 55 107 participants improved.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/strep_tb.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"RCT of Streptomycin Therapy for Tuberculosis — strep_tb","text":"data set reconstructed best ability paper British Medical Journal 1948, entitled, Streptomycin Treatment Pulmonary Tuberculosis, pages 769-782 October 30, 1948 edition, authored Streptomycin Tuberculosis Trials Committee. can find pdf Streptomycin TB.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/strep_tb.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"RCT of Streptomycin Therapy for Tuberculosis — strep_tb","text":"Streptomycin Tuberculosis trial 1948 considered first modern randomized, placebo-controlled clinical trial, done part limited supplies streptomycin UK World War II.  publication seems bit primitive today, without standard features like proper Table 1, creative use graphs display baseline characteristics study sample  strikingly, ethics committee approval, consent.  can read pdf original journal article Streptomycin TB Study.  first series 3 trials, initial effectiveness Streptomycin established, rapid resistance developed, significant side effects occurred dose 2 grams streptomycin. type resistance also occurred another new anti-tubercular therapy time, PAS (Para-Amino-Salicylate). Subsequent trials B C evaluated different doses combinations Streptomycin PAS, published together 1952 BMJ, pdf available 1952 Three Streptomycin TB Studies Summarized.  Commentary conduct trials one MD investigators can found MD Clinical Trialist Commentary.  Commentary design analysis trials statistician . Bradford Hill can found Statistican Commentary.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/supraclavicular.html","id":null,"dir":"Reference","previous_headings":"","what":"Study of Supraclavicular Anesthesia — supraclavicular","title":"Study of Supraclavicular Anesthesia — supraclavicular","text":"data set contains 103 patients scheduled undergo upper extremity procedure suitable supraclavicular anesthesia. Patients randomly assigned either (1) combined group-ropivacaine mepivacaine mixture; (2) sequential group-mepivacaine followed ropivacaine. number demographic post-op pain medication variables (fentanyl, alfentanil, midazolam) collected. primary outcome time 4-nerve sensory block onset. dataset cleaned relatively complete. outliers data problems (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/supraclavicular.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Study of Supraclavicular Anesthesia — supraclavicular","text":"","code":"supraclavicular"},{"path":"https://higgi13425.github.io/medicaldata/reference/supraclavicular.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Study of Supraclavicular Anesthesia — supraclavicular","text":"data frame 103 observations 17 variables subject Subject ID, numeric, range: 1-103 group Anesthetic group, numeric, 1 = Mixture; 2 = Sequential gender Gender, numeric, 1 = Male; 0= Female bmi Body mass index (kg/m^2), numeric, range:19-43.5 age Age (years), numeric, range:18-74 fentanyl Fentanyl pain medication (micrograms), numeric, range: 0-250.0 alfentanil Alfentanil pain medication (milligrams), numeric, range: 0-4.3 midazolam Midazolam hypnotic-sedative medication, numeric, range: 0-9.0 onset_sensory Time 4 nerve sensory block onset , onset_sensory block failed observed worst outcome minutes patient (50 minutes), numeric, range: 0-50.0 onset_first_sensory Time first sensory block minutes, block failed, value 15 minutes, numeric, range: 6-15.0 onset_motor Time complete motor block , motor block failed, observed worst outcome minutes patient (50 minutes), numeric, range: 1-50.0 nerve_block_censor block failed, numeric, 0 = nerve block succeeded, 1 = block failed (censored) med_duration Time onset 4 nerve sensory block first request analgesic medication (hours), numeric, range: 0-48.0 med_censor Patients take analgesic censored 48 hours, numeric, 0 = nerve  succeeded, 1 = block failed (censored) vps_rest Maximum postop verbal pain score (rest),  11 point Likert scale (0-10), numeric, range: 0-10 vps_movement Maximum postop verbal pain score (movement),  11 point Likert scale (0-10), numeric, range: 0-10 opioid_total Total opioid consumption milligrams, numeric, range: 0-225.0","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/supraclavicular.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Study of Supraclavicular Anesthesia — supraclavicular","text":"data study Roberman et al. 'Combined Versus Sequential Injection Mepivacaine Ropivacaine Supraclavicular Nerve Blocks'. Reg Anesth Pain Med 2011; 36:145-50.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/supraclavicular.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Study of Supraclavicular Anesthesia — supraclavicular","text":"choice anesthetic technique combined suitable plan postoperative analgesia can facilitate early discharge, improve patient comfort, increase overall satisfaction. Patients painful procedures undergo general anesthesia 2- 5-fold greater risk unplanned overnight admissions compared regional anesthesia. Regional anesthetic techniques peripheral nerve blocks especially favored surgeries extremities. rapid onset block prolonged postoperative analgesia desired characteristics regional anesthesia. choice local anesthetics combinations thereof can greatly influence effectiveness block, onset time, duration postoperative analgesia, need opioid use, patient satisfaction. Mepivacaine ropivacaine commonly used peripheral nerve blocks, drawbacks short duration 1.5% mepivacaine delayed onset 0.5% ropivacaine. ideal local anesthetic high potency, low toxicity, rapid onset, prolonged duration exist yet. Investigators therefore tried mixtures local anesthetics attempt combine advantages conflicting results. potential problem mixing drugs dilutes effects . Thus, mixture rapid-onset drug mepivacaine long-acting one ropivacaine may well result slower onset mepivacaine alone shorter duration action ropivacaine alone. contrast, sequential administration amounts drugs may preserve desirable features . Objective: study investigates whether sequential supraclavicular injection 1.5% mepivacaine followed 90 seconds later 0.5% ropivacaine provides quicker onset longer duration analgesia equidose combination 2 local anesthetics.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/theoph.html","id":null,"dir":"Reference","previous_headings":"","what":"Cohort Study of the Pharmacokinetics of Oral Theophylline — theoph","title":"Cohort Study of the Pharmacokinetics of Oral Theophylline — theoph","text":"Results Cohort Study Pharmacokinetics Oral Theophylline, plasma concentrations time (details available variable definitions).","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/theoph.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Cohort Study of the Pharmacokinetics of Oral Theophylline — theoph","text":"","code":"theoph"},{"path":"https://higgi13425.github.io/medicaldata/reference/theoph.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Cohort Study of the Pharmacokinetics of Oral Theophylline — theoph","text":"data frame 132 observations 5 variables Subject subject id number participant; type: ordinal factor Wt Weight kilograms; type: double Dose Dose milligrams per kilogram; type: double Time Time initial dose hours; type: double conc Concentration theophylline plasma micrograms per milliliter' type: double","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/theoph.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Cohort Study of the Pharmacokinetics of Oral Theophylline — theoph","text":"Boeckmann, . J., Sheiner, L. B. Beal, S. L. (1994), NONMEM Users Guide: Part V, NONMEM Project Group, University California, San Francisco. Note original data collector, Robert . Upton, credited, original work cited.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/theoph.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Cohort Study of the Pharmacokinetics of Oral Theophylline — theoph","text":"data set pharmacokinetic study oral dosing anti-asthma medication, theophylline, 12 subjects 25 hours, published Dr. Robert . Upton around 1980. original publication, , unclear cited. data used package named nlme, reported Boeckmann, .J., et al.Dr. Upton publish several papers theophylline pharmacokinetics around 1980-1984, data one . Theophylline methylxanthine anti-asthma medication, acts bronchodilator, secondary effects strengthen diaphragm contraction, reduce pulmonary artery pressures, reduce mast cell release. can administered intravenous, oral, rectal suppository routes. subject Study (oral route) received single oral dose theophylline. Blood samples taken frequent intervals first 25 hours dosing, quantity theophylline plasma time point measured micrograms per milliliter.  Unfortunately, theophylline plasma level blood varies considerably patients, differences drug clearance, affected body mass, age, smoking, liver heart function, viral infections. complicate drug , important interactions number common medicines can increase decrease drug level. subject study received single oral dose 300 mg theophylline, converted milligrams per kilogram dose. Blood samples taken frequent intervals next 25 hours dosing, quantity theophylline plasma time point measured micrograms per milliliter plasma.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/thiomon.html","id":null,"dir":"Reference","previous_headings":"","what":"Deidentified Laboratory Data on IBD Patients using Thiourines for at least 4 weeks and their Eventual Remission/Active Status after at least 12 Weeks of Therapy. — thiomon","title":"Deidentified Laboratory Data on IBD Patients using Thiourines for at least 4 weeks and their Eventual Remission/Active Status after at least 12 Weeks of Therapy. — thiomon","text":"dataset containing laboratory data outcomes IBD patients Thiopurine therapy University Michigan variables data set follows: days_of_life Numeric. Range: 1207-32356. 1 missing value. plt Platelet Count. Numeric. Range: 11-1114. 4 missing values. mpv Mean Platelet Volume. Numeric. Range: 5.3-13.5. 21 missing values. un Blood Urea Nitrogen. Numeric. Range: 2-118. 53 missing values. wbc White Blood Cell Count. Numeric. Range: 0.7-33.5. missing values. hgb Hemoglobin. Numeric. Range: 4.5-18.6. 4 missing values. hct Hematocrit. Numeric. Range: 13.7-55.2. 3 missing values. rbc Red Blood Cell Count. Numeric. Range: 1.57-7.04. 3 missing values. mcv Mean Corpuscular (RBC) Volume. Numeric. Range: 56.5-124. 3 missing values. mch Mean Corpuscular (RBC) Hemoglobin. Numeric. Range: 16.7-42.3. 7 missing values. mchc Mean Corpuscular (RBC) Hemoglobin per Cell. Numeric. Range: 28.2-38.0. 7 missing values. rdw Red cell Distribution Width. Numeric. Range: 11.3-39.7. 3 missing values. neut_percent Percent Neutrophils WBC count. Numeric. Range: 17-98.1. missing values. lymph_percent Percent Lymphocytes WBC count. Numeric. Range: 1-67.9. missing values. mono_percent Percent Monocytes WBC count. Numeric. Range: 0-30.3. missing values. eos_percent Percent Eosinophils WBC count. Numeric. Range: 0.5-29.3. 6 missing values. baso_percent Percent Basoophils WBC count. Numeric. Range: 0.2-5.3. 6 missing values. sod Sodium. Numeric. Range: 116-151. missing values. pot Potassium. Numeric. Range: 2.6-10.1. 1 missing value. chlor Chloride. Numeric. Range: 83-126. missing values. co2 Bicarbonate (CO2). Numeric. Range: 12-40. 5 missing values. creat Creatinine. Numeric. Range: 0.2-8.4. missing values. gluc Glucose. Numeric. Range: 41-486. missing values. cal Calcium. Numeric. Range: 6.5-11.8. 1 missing value. prot Protein. Numeric, range 2.9-10, 0 missing values alb Albumin. Numeric, range 1.2-5.5, 0 missing values ast Aspartate Transaminase. Numeric, range 5-7765, 0 missing values alt Alanine Transaminase. Numeric, range 1-10666, 18 missing values alk Alkaline phosphatase. Numeric, range 13-1938, 0 missing values tbil Total Bilirubin. Numeric, range 0.09-27, 0 missing values active Active Inflammation despite Thiopurines > 12 weeks. Numeric, range 0-1, 0 missing values remission Remission Inflammation Thiopurines > 12 weeks. Numeric, range 0-1, 0 missing values","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/thiomon.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Deidentified Laboratory Data on IBD Patients using Thiourines for at least 4 weeks and their Eventual Remission/Active Status after at least 12 Weeks of Therapy. — thiomon","text":"","code":"thiomon"},{"path":"https://higgi13425.github.io/medicaldata/reference/thiomon.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Deidentified Laboratory Data on IBD Patients using Thiourines for at least 4 weeks and their Eventual Remission/Active Status after at least 12 Weeks of Therapy. — thiomon","text":"data frame 5168 observations 32 variables. numeric variables.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/thiomon.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Deidentified Laboratory Data on IBD Patients using Thiourines for at least 4 weeks and their Eventual Remission/Active Status after at least 12 Weeks of Therapy. — thiomon","text":"data set Akbar K. Waljee Peter D. Higgins, de-identified data CBC chemistry testing University Michigan development machine learning algorithm predict response thiopurine medications IBD patients. data set contains individual laboratory values, age days, outcome (active remission). data anonymized, time-shifted.  published Clin Gastroenterol Hepatol. 2010 Feb;8(2):143-150.","code":""},{"path":"https://higgi13425.github.io/medicaldata/reference/thiomon.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Deidentified Laboratory Data on IBD Patients using Thiourines for at least 4 weeks and their Eventual Remission/Active Status after at least 12 Weeks of Therapy. — thiomon","text":"Data laboratory values complete blood count chemistry panel least 4 weeks start thiopurine therapy IBD patients. University Michigan Hospital Ann Arbor, USA. data anonymized, time-shifted. Age reported days life. Random Forest approaches can work well modeling Active Remission status. published Clin Gastroenterol Hepatol. 2010 Feb;8(2):143-150.","code":""},{"path":[]},{"path":"https://higgi13425.github.io/medicaldata/news/index.html","id":"medicaldata-0209000","dir":"Changelog","previous_headings":"","what":"medicaldata 0.2.0.9000","title":"medicaldata 0.2.0.9000","text":"dev version, adding examples vignettes added cath Frank Harrell added abm Frank Harrell","code":""},{"path":"https://higgi13425.github.io/medicaldata/news/index.html","id":"medicaldata-020","dir":"Changelog","previous_headings":"","what":"medicaldata 0.2.0","title":"medicaldata 0.2.0","text":"CRAN release: 2021-08-16 stable version datasets now complete documentation help() packagedown site built updated 0.2.0, CRAN 2021-08-16.","code":""},{"path":"https://higgi13425.github.io/medicaldata/news/index.html","id":"medicaldata-0109000","dir":"Changelog","previous_headings":"","what":"medicaldata 0.1.0.9000","title":"medicaldata 0.1.0.9000","text":"Added NEWS.md file track changes package.","code":""}]
